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1 Introduction 
Diabetes mellitus type 2 is a chronic metabolic disorder of multiple etiology and 
characterized by insulin resistance and progressive dysfunction of pancreatic islet 
cells. The meal-stimulated insulin secretion from β-cells is reduced and fails to meet 
the demands of the insulin-resistant state (Kahn et al. 2006). The disease is 
considered to be a world health crisis. In conjunction with genetic susceptibility, 
particularly in certain ethnic groups, type 2 diabetes mellitus is brought on by 
environmental and behavioral factors such as a sedentary lifestyle, overly rich 
nutrition and obesity (Leahy 2005). At the turn of this century, 171 million individuals 
were estimated to have diabetes, 90 % of which were considered cases of type 2 
diabetes mellitus. This number is expected to increase up to 366 million by 2030 
(Wild et al. 2004). Due to its chronic character, gravity of secondary lesions and 
agents necessary to control these, type 2 diabetes mellitus is associated with very 
high expenses ($ 132 billion in 2002 in the U.S.A.) (Hogan et al. 2003). Importantly, a 
reduced relative β-cell mass coming along with increased β-cell apoptosis have been 
reported in type 2 diabetic patients (Butler et al. 2003; Sakuraba et al. 2002). 
Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 
(GLP-1) are defined as incretin hormones, mediating the incretin effect which 
describes the phenomenon that an oral glucose load leads to a higher insulin 
response than an intravenous glucose load (Elrick et al. 1964; McIntyre et al. 1964). 
Secreted from enteroendocrine cells within the intestine in response to nutrient 
ingestion, both incretin hormones bind to their specific receptor on the pancreatic β-
cells and potentiate glucose-dependent insulin secretion, accounting for 20 to 60 % 
of total insulin secretion depending on the glucose load (Nauck et al. 1986a; Nauck 
et al. 1986b). One facet of type 2 diabetes mellitus is a reduced to almost absent 
incretin effect mainly originating from a significantly reduced insulinotropic action of 
GIP (Nauck et al. 1993). Based on the knowledge that the insulinotropic effect of the 
other incretin hormone, GLP-1, is vastly preserved, incretin hormone based 
therapeutics have already been established, but quite a few of them are still in the 
developmental phase. 
Since the role of the GIP/GIP-receptor (GIPR) axis in the pathogenesis of type 2 
diabetes mellitus needs to be clarified, the aim of this work was the generation and 
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genotypic as well as phenotypic characterization of transgenic pigs expressing a 
dominant-negative GIP-receptor under control of the rat insulin 2 (Ins2) gene 
promoter. A genetically modified large animal model is important to elucidate 
pathogenetic consequences associated with impairment of the GIP/GIPR axis as well 
as for translational studies, e.g. therapeutic trials. 
Lentiviral gene transfer made it possible to efficiently generate a pig animal model 
which is more clinically relevant than rodent models owing to the high similarities of 
human and porcine anatomy and physiology. 
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2 Review of the literature 
2.1 Viral transgenesis 
Transgenic animals can be broadly defined as animals that contain recombinant DNA 
molecules in their genome that have been introduced by human intervention (Wall 
1996). The principle of viral transgenensis is the introduction of foreign genes into 
preimplantation embryos with the aid of viruses. Retroviruses are characterized by 
their ability to reversely transcribe their viral genome into double-stranded (ds) DNA 
by using an enzyme called reverse-transcriptase and integrate it into the host 
genome as a so-called provirus. Thus, the virus serves as a shuttle for the transfer of 
external genes (transgenes) into the host genome. Integration of retroviruses 
carrying foreign DNA as well as germ line integration and transmission was first 
described by Jaenisch and coworkers using the murine leukemia virus (MLV) 
(Jaenisch et al. 1975; Jaenisch 1976). 
 
2.1.1 Lentiviruses 
The lentiviruses belong to the family of Retroviridae which possess the enzyme 
reverse transcriptase and maybe oncogenic. The family of retroviruses can be 
divided into two groups depending on the organization of their genome: simple and 
complex retroviruses. The genus Lentivirinae belongs to the latter group (Coffin 
1992). They are enveloped viruses and their genome is a dimer of a single-stranded 
RNA of positive polarity. As all retroviruses, lentiviruses have gag, pol and env genes 
coding for structural virion proteins that form the matrix, capsid, and the 
nucleoprotein complex, viral enzymes (reverse transcriptase, integrase, protease) 
and envelope glycoproteins that are displayed on the surface of the virus (Goff 2001). 
In addition lentiviruses contain additional accessory and regulatory genes. 
The most prominent and best studied representative of lentiviruses is the human 
immunodeficiency virus (HIV). But lentiviruses have also been isolated from other 
species, for example the visna/maedi virus in sheep, the equine infectious anemia 
virus (EIAV) in the horse and the feline immunodeficiency virus (FIV) in the cat. 
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2.1.2 Retroviral life cycle 
Following infection of the host cell, reverse transcription of the virus RNA takes place 
in the cytoplasm. The viral genome is flanked by regulatory control sequences which 
are essential for reverse transcription and integration of viral genetic information 
(Starcich et al. 1985; Kao et al. 1987). The so-called R-region (“redundant”) attaches 
directly to the Cap-structure at the 5’-end of the viral genome and also exists at the 
3’-end with identical nucleotide sequence and orientation (Starcich et al. 1985). The 
U5-region (“unique”) located at the 5’-end is important for the integration of the 
provirus into the host genome. A primer binding site (PB) is connected to the U5-
region followed by a splice-donor-site. The splice-donor-site is probably responsible 
for the generation of all spliced mRNA molecules (Starcich et al. 1985). Additionally, 
a so-called ψ sequence is located at the 5’-end, which is essential for the packaging 
of viral RNA into the virus particle (Berglund et al. 1997; Clever et al. 2000); (Figure 
2.1). The U3-region located at the 3’-end of the virus genome is reverse transcribed 
in duplicate and subsequently copied to the 5’-end while the U5-region at the 5’-end 
is copied to the 3’-end (LTR conversion) forming tandem repeats which are called 
long-terminal repeats (LTR’s). LTR’s are necessary for reverse transcription of the 
vector RNA and integration of the proviral DNA into the host genome. (Starcich et al. 
1985). 
Subsequently, the preintegration complex is translocated to the nucleus. Lentiviruses 
differ in their basic requirements for entering the nucleus from prototypic retroviruses. 
While simple retroviruses can only enter the nucleus during mitosis when the nuclear 
membrane is disassembled (Miller et al. 1990), lentiviruses are able to access the 
nucleus of non-dividing cells through the nuclear pores (Follenzi et al. 2000; Zennou 
et al. 2000). Thus, integration into the genome prior to the first cell division may 
minimize the risk of mosaic formation. As soon as virus DNA has reached the 
nucleus, DNA is integrated into the host genome forming a provirus. The provirus 
uses the host-cell machinery for gene expression. Therefore the U3-region contains 
promoters as well as cis-acting sequences which are binding sites for cellular 
proteins. Thus, the U3-region is also important for gene expression of the provirus. 
When translation of the virus genome is completed, new virus particles are 
assembled and released from the host cell by budding of the cell membrane (Pfeifer 
& Verma 2001). 
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Figure 2.1:  RNA genome of a retrovirus; figure from Modrow et al., 2003. 
 
2.1.3 Basic outline of viral vectors 
In general non-integrating and integrating viral vectors are known. While non-
integrating vectors get lost after several cell divisions, integrating viral vectors 
integrate permanently into the host genome and outlast germline transmission. 
Lentiviruses, prototypic retroviruses or adeno-associated viruses (AAV) are most 
commonly used for construction of integrating vectors. To generate a viral vector, 
wild-type virus genes for infection, replication and pathogenesis are deleted. In such 
replication-defective viruses, the life cycle is cut down to one round of infection. 
Afterwards, the transgene is integrated into the viral vector together with the 
designated promoter and flanked by the LTR’s. Last, the viral particles are produced 
by helper cells through the expression of essential viral proteins in trans (Pfeifer 
2004). Being integrated into the host genome, the provirus is not able to form 
progeny virus, but the expression cassette on the vector can still be transcribed. 
 
2.1.4 Lentiviral vectors 
Lentiviral vectors are mostly based on the human immunodeficiency virus 1 (HIV-1). 
An advancement in biosafety has been the establishment of third generation HIV 
based vector systems (Dull et al. 1998). Apart from HIV-1, lentiviral vectors have 
been derived from HIV-2 (Poeschla et al. 1998a), feline immunodeficiency virus (FIV) 
(Poeschla et al. 1998b), equine infectious anemia virus (EIAV) (Olsen 1998), simian 
immunodeficiency virus (SIV) (Mangeot et al. 2000), and maedi/visna virus 
(Berkowitz et al. 2001). 
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Further advances have been achieved through the generation of so-called self-
inactivating vectors (SIN-vectors) as viral enhancer and promoter sequences within 
the LTR’s have been deleted in this vectors (Miyoshi et al. 1998; Zufferey et al. 
1998). The risk for insertional activation of cellular oncogenes through the promoter 
and enhancer elements of the proviral LTR’s was addressed with insertion of self-
inactivating mutations in just these elements. In addition it was postulated that SIN 
vectors might avoid gene silencing as the active viral promoter sequence might 
attract the host silencing machinery to the integrated provirus (Pfeifer et al. 2002). 
This assumption proved false since epigenetic regulation was found in transgenic 
pigs generated by lentiviral gene transfer as well as in murine embryonic carcinoma 
P19 cells transduced with lentiviral SIN vectors (Hofmann et al. 2006; He et al. 2005). 
However, the extent of lentiviral silencing was much lower than in the initial studies 
using prototypic retroviruses (Jaenisch 1976). The lack of a viral promoter requires 
the incorporation of a heterologous promoter driving the transgene expression and so 
allowing ubiquitous as well as tissue-specific expression of the transgene (Pfeifer et 
al. 2002; Lois et al. 2002). 
Another special feature is the incorporation of a polypurine tract (ppt) of the pol gene 
into the lentiviral vector which enhances the import of the viral genome into the 
nucleus (Follenzi et al. 2000; Zennou et al. 2000). In addition, the insertion of the 
posttranscriptional regulatory element of the woodchuck hepatitis virus enhances 
transgene expression in a promoter- and transgene-independent manner (Zufferey et 
al. 1999).  
Besides genes located on the vector construct, several other viral elements are 
located on different packaging constructs. Usually, gag and pol proteins are needed. 
For ideal vector production the rev gene needs to be present which interacts with so-
called RREs (rev responsive elements) and promotes the nuclear export of unspliced 
gag-pol mRNA and the genomic RNA of the lentiviral vector (Delenda 2004). 
Expression of the rev gene through a separate packaging construct could ameliorate 
biosafety (Gasmi et al. 1999). Finally, the gene coding for the env protein, 
determining the tropism of the virus, is located on a separate packaging vector. In 
order to expand the natural tropism of lentiviruses, env was replaced by envelope 
proteins of heterologous viruses. To provide a broad host range that can be infected, 
most of the lentiviral vectors are pseudotyped with the G-protein of the 
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vesiculostomatitis virus (VSV) (Akkina et al. 1996; Naldini et al. 1996). This method 
also stabilizes viral particles so they can easily be concentrated by ultracentrifugation 
and are more resistant to freezing and thawing processes (Lever et al. 2004). In 
addition, infection of host cells is no more carried out by fusion of the virus particle 
with the host cell but through the endocytosis signaling cascade (Aiken 1997). 
Packaging constructs are either transfected transiently into the packaging cells or a 
cell line is established that stably expresses the viral proteins. Mostly, HEK 293T 
cells, a human embryonic kidney cell line, transiently transfected with the vector and 
packaging plasmids are used. With this method high lentivirus titers (>109 infectious 
units (IU)/ml) can be achieved (Pfeifer & Verma 2001). Thus, the RNA is packaged 
into viral particles and the lentiviral virions are released into the culture medium of 
packaging/producer cells by budding. 
 
2.1.5 Lentiviral transgenesis in the pig 
Lentiviral transgenesis was first reported in mice and rats (Pfeifer et al. 2002; Lois et 
al. 2002). As the zona pellucida is a barrier for lentiviral infection, zygotes had to be 
denuded or the lentiviral particles had to be injected into the perivitelline space. The 
latter method turned out to be the only practical method for pigs due to high 
embryonic losses after denudation (Hofmann et al. 2003). Transgenic pigs generated 
by lentiviral gene transfer using a HIV-1 based vector system which carries the green 
fluorescent protein (GFP) under control of the ubiquitously expressing 
phosphoglycerate kinase promoter (PGK) were first described in 2003 (Hofmann et 
al. 2003). Seventy percent of animals born (13.1% of infected and transferred 
embryos) turned out to be transgenic. One to twenty lentiviral integrants were 
detected by Southern blot analyses. Thirty (94%) of the 32 transgenic pigs expressed 
the transgene. Also germline transmission was confirmed (Hofmann et al. 2003). 
Another group who generated transgenic pigs on the basis of an equine infectious 
anemia virus derived vector achieved 92% of transgenic pigs (31% of the transferred 
embryos). Ninety-five percent of the founder animals expressed the GFP transgene 
under the control of the human cytomegalovirus promoter (CMV). Pigs revealed one 
to five integrants. Germline transmission was not evaluated (Whitelaw et al. 2004). 
Thus, lentiviral transgenesis showed a 27- to 50-fold increase in efficiency compared 
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to DNA microinjection (Fassler 2004; Whitelaw et al. 2004). The efficiency of DNA 
microinjection, the most wide-spread technology to generate transgenic animals 
(Clark & Whitelaw 2003), is generally low. In the mouse, approximately 2.6% of 
transgenic offspring per injected and transferred embryos can be obtained while in 
the pig the efficiency is even lower, ranging around 0.9% (Wall 1996). 
One reason for this is that the pronucleus of porcine zygotes can hardly be targeted 
with the injection capillary because the cytoplasm of porcine zygotes is opaque. 
Increased efficiency could considerably lower the costs incurred by generation of a 
transgenic pig which were estimated at $ 30,000 (Fassler 2004). However, the size of 
the transgene plus its internal promoter within the lentiviral construct is limited to 8 kb 
because the maximal packaging capacity of an HIV-1 based vector particle is ~10 kb 
while DNA transfer capacity of DNA-microinjection is basically unlimited. The 
phenomenon of DNA-hypermethylation was examined in pigs of the F1-generation 
after segregation of the integration sites had taken place. Actually, one third of the 
integration sites exhibited low expression levels and hypermethylation indicating that 
methylation plays a role in lentiviral expression (Hofmann et al. 2006). Also 
insertional mutagenesis or activation of proto-oncogenes following integration of the 
lentiviral construct close to a proto-oncogene promoter may be possible side-effects 
of lentiviral transgenesis (Pfeifer 2004). However, it has been shown that prototypic 
retroviruses tend to integrate in genomic sequences surrounding the transcriptional 
start site (Wu et al. 2003; Wu & Burgess 2004), while lentiviruses do not (Schroder et 
al. 2002). 
 
2.2 The incretin hormone system 
2.2.1 History of the incretin concept 
As early as 1932, La Barre introduced the term “incretin” for the first time. He and his 
colleagues had performed cross-circulation experiments and demonstrated that the 
intravenous injection of crude secretin, a term which originally involved all ingredients 
of a mucosal extract from the small intestine, produced hypoglycemia in dogs via 
stimulation of the endocrine pancreas. They concluded that crude secretin contained 
two active principles: “incretin” stimulating the internal secretion of the pancreas and 
 8
Review of the literature 
“excretin” stimulating the exocrine pancreas (Creutzfeldt 2005). Over 20 years later, 
in 1964, as soon as it was possible to determine serum insulin concentrations by 
radioimmunoassay, the incretin effect was determined as the phenomenon of an oral 
glucose load eliciting a higher insulin response than an intravenous glucose load 
(Elrick et al. 1964; McIntyre et al. 1964). From this time, all known gastrointestinal 
hormones were proved for their properties of an incretin. Secretin, vasoactive 
intestinal polypeptide (VIP), glucagon, gastrin and cholecystokinin (CCK) for instance 
stimulated insulin secretion but only if given in supraphysiologic doses (Creutzfeldt 
1979). At this point none of the known hormones met the criteria of an incretin which 
are as follows (Creutzfeldt 2005): 
 
• Release from gut endocrine cells after ingestion of nutrients, especially 
glucose 
• Glucose dependency of the glucose lowering effect, i. e. the glucose lowering 
effect occurs only in the presence of elevated blood glucose levels 
• Stimulation of insulin secretion in a concentration that is easily achieved after 
nutrient ingestion (not only after administration of supraphysiological levels) 
 
The first incretin hormone was discovered in 1970 by John C. Brown as a 
contaminant of impure cholecystokinin-pancreozymin extracts and was named 
gastric inhibitory polypeptide (GIP) due to its inhibitory effect on gastric acid secretion 
in dogs (Brown et al. 1970; Brown & Dryburgh 1971). A few years later the 
insulinotropic effect of GIP was discovered (Dupre et al. 1973) and the meaning of 
the acronym GIP changed into glucose-dependent insulinotropic polypeptide, since 
an inhibitory effect of GIP on gastric acid secretion was seen only at pharmacologic 
doses, whereas its incretin action occurred at physiologic levels. However, several 
different experimental approaches revealed that GIP cannot be the only incretin. In 
vivo immunoneutralization of GIP reduced but did not completely ablate the incretin 
effect in response to an oral glucose load. Significant insulin-releasing activities 
remained after removal of GIP from intestinal mucosa preparation as well as from 
venous perfusate of an isolated perfused rat intestine (Ebert & Creutzfeldt 1982; 
Ebert et al. 1983; Levin et al. 1979). Patients who underwent intestinal resection with 
near total loss of the ileum showed a smaller incretin effect than patients with larger 
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amounts of residual ileum, although GIP levels were identical in all groups (Lauritsen 
et al. 1980). In 1985, the insulinotropic effect of the second incretin, glucagon-like 
peptide 1 (GLP-1), was discovered (Schmidt et al. 1985). 
 
2.2.2 Quantification of the incretin effect 
The incretin effect describes the phenomenon that an oral glucose load leads to a 
much higher insulin secretory response than does an intravenous glucose load 
(Elrick et al. 1964; McIntyre et al. 1964). To precisely quantify the extent of the 
incretin effect related to the total insulin response following nutrient stimulation, a 
comparison of the insulin secretory response after oral and “isoglycemic” intravenous 
glucose administration is state of the art. Here “isoglycemic” describes an 
intravenous glucose infusion leading to a similar glycemic profile as after an oral 
glucose load (Nauck et al. 2004). 
The quantitative impact of the incretin effect was shown to be dependent on the size 
of the glucose load and ranged between 20 and 60% (C-peptide response) in healthy 
human subjects following an oral glucose load of 25 to 100 g (Nauck et al. 1986a; 
Nauck et al. 1986b). It is also important to note that the two incretins, GIP and GLP-
1, have additive but not potentiating effects on insulin secretion in humans (Nauck et 
al. 1993a). However, GIP was found to be able to release GLP-1 in rodents 
(Herrmann-Rinke et al. 1995). Quantitatively, the contribution of GIP to the incretin 
effect was reported to be more important (Nauck et al. 1993a). Despite similar 
glucose-concentration dependence of their insulinotropic activities, higher plasma 
concentrations of GIP, both in the basal and postprandial state, were detected 
compared to GLP-1 levels (Nauck 1999). 
To define the contribution of both incretin hormones or either one of them on insulin 
secretion, numerous studies were carried out in rodents using GIP receptor (GIPR) 
and GLP-1 receptor (GLP-1R) antagonists. Studies performed in rats using the GIPR 
antagonist GIP (7-30)-NH2 reduced postprandial insulin release by 72% (Tseng et al. 
1996b). Application of the GLP-1 receptor antagonist Exendin (9-39) also led to a 
marked decrease of insulin secretion by 48% (Wang et al. 1995). Another study 
showed a reduction of insulin secretion by 32% and 54% after Exendin (9-39) and 
GIP (7-30)-NH2 application following an intragastric glucose load (Tseng et al. 1999). 
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GIP (6-30)-amide was found to be a potent GIPR antagonist with an equivalent 
binding affinity to the GIPR compared to the bioactive GIP (1-42) and reduced cAMP 
rise by 58% in chinese hamster kidney (CHO-KI) cells stably expressing the rat 
pancreatic islet GIP receptor (Gelling et al. 1997a). 
 
2.2.3 The enteroinsular axis 
The term enteroinsular axis formed by Unger and Eisentraut comprises the 
collectivity of signaling pathways between the gut and the endocrine pancreas 
meaning nutrient, neural and hormonal signals (Unger & Eisentraut 1969). 
 
2.2.4 Neural components 
Vagal stimulation following nutrient ingestion is thought to augment insulin secretion. 
An example for this is the cephalic phase of insulin secretion which has been 
demonstrated in dogs, rats and humans (Ebert & Creutzfeldt 1987). It has been 
shown that several gastrointestinal neuropeptides with insulinotropic inhibitory or 
stimulatory activity are present in pancreatic nerves: stimulators such as gastrin-
releasing peptide (GRP), cholecystokinin (CCK), gastrin and vasoactive intestinal 
polypeptide (VIP) as well as inhibitors such as somatostatin may function as 
neurotransmitters. The gastrointestinal neural system may participate in the entero-
insular axis in two ways: regulation of the release of an incretin into the blood stream 
and by direct stimulation of the islets via nerve fibres (Creutzfeldt 1979). However, 
whether denervation of the pancreas impairs glucose tolerance is discussed 
controversial. In humans, the incretin effect of pancreas-kidney-transplanted type 1 
diabetic patients, whose functioning pancreas is denervated, was shown to be 
preserved (Nauck et al. 1993b). 
 
2.2.5 Glucagon-like peptide 1 (GLP-1) 
GLP-1 is a tissue-specific posttranslational proteolytic product of the proglucagon 
gene that is released from intestinal L-cells in response to nutrient ingestion (Mojsov 
et al. 1987; Kreymann et al. 1987). L-cells are located mainly in the distal ileum and 
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the colon. Besides GLP-1, other gastrointestinal hormones like enteroglucagon, 
peptide YY and GLP-2 are secreted from L-cells following glucose and fat ingestion 
(Holst 1994). Secretion of GLP-1 occurs in a biphasic pattern starting with an early 
phase (within 10-15 minutes) that is followed by a longer (30-60 minutes) second 
phase (Herrmann et al. 1995). In humans, GLP-1 exists mainly as a COOH-
terminally amidated form, GLP-1-(7-36)-amide, and a minor glycine extended form, 
GLP-1-(7-37) (Orskov et al. 1994). Both bioactive forms are equipotent concerning 
their insulinotropic activity. GLP-1 is a target for the dipeptidyl peptidase-4 (DPP-4) 
and the active forms are rapidly degraded (t1/2 < 2 minutes) to GLP-1-(9-36)-amide 
and GLP-1-(9-37) (Deacon et al. 1995). GLP-1 exhibits biological functions in 
numerous tissues mediated through binding to its specific receptor, the GLP-1 
receptor. In the pancreas it acts as an incretin hormone but also inhibits glucagon 
secretion (Nauck et al. 2002). Both actions are glucose-dependent. As a result of its 
impact on insulin and glucagon secretion, glucose production in the liver is lowered 
while glucose uptake and storage in peripheral tissues (fat, muscle) is increased. 
Additionally, GLP-1 triggers satiety, thus reduces calorie intake which was evaluated 
by intracerebroventricular as well as systemic application of GLP-1 (Turton et al. 
1996; Flint et al. 1998). Further, glucagon-like peptide-1 reduces gastric emptying 
leading to a delayed nutrient transfer to the duodenum, resulting in a diminished rise 
of blood glucose levels. Surprisingly, the action of GLP-1 as an incretin hormone and 
its effect on gastric emptying act antidromic on total insulin secretion (Nauck et al. 
1997). GLP-1 was found to exhibit mitogenic and anti-apoptotic functions on the β-
cell in vitro and in vivo (Farilla et al. 2002; Farilla et al. 2003; Buteau et al. 2004). 
Moreover GLP-1 was reported to exhibit cardioprotection (Baggio & Drucker 2007). 
Nearly sustained insulinotropic action of GLP-1 in type 2 diabetic patients revealed its 
therapeutic potential to correct the reduced incretin effect in type 2 diabetic patients 
mainly initiated by reduced insulinotropic action of GIP (Nauck et al. 1993). 
 
2.2.6 Glucose-dependent insulinotropic polypeptide (GIP) 
GIP is a single 42 amino acid peptide (Brown & Dryburgh 1971; Moody et al. 1984) 
which is highly conserved with more than 90% amino acid sequence homology 
comparing the human, bovine, porcine, mouse and rat GIP sequence (Yip & Wolfe 
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2000). Bioactive GIP itself is derived by proteolytic processing of its preprohormone 
precursor, 153-amino acids in length in humans (144-amino acids in length in rats) 
(Yip & Wolfe 2000). A signal peptide as well as a N-terminal peptide and a C-terminal 
peptide which functions are unknown so far flank the bioactive GIP (1-42). Studies 
performed in prohormone convertase (PC) 1/3 or PC2 knockout mice revealed PC1/3 
to be responsible for processing of the proGIP protein. Moreover, different cell lines 
expressing either PC1/3 or PC2 and overexpressing preproGIP confirmed that PC2 
can indeed mediate processing to GIP but PC1/3 seem to be mainly responsible for 
the release of bioactive GIP which is among other things related to the fact that PC2 
was not found in intestinal GIP expressing cells (Ugleholdt et al. 2006). In rodents 
and humans, the GIP gene is expressed in stomach as well as in intestinal K-cells 
while in rats GIP was also found to be expressed in the submandibular salivary gland 
(Fehmann et al. 1995). 
 
 
 
Figure 2.2:  Generation of bioactive GIP 
(A) proGIP gene, (B) proGIP mRNA, (C) proGIP protein, E1-E6: Exon 1 – Exon 6, S: signal 
peptide, N: N-terminal peptide, C: C-terminal peptide, figure modified from Baggio 2007. 
 
2.2.7 GIP secretion, metabolism, degradation 
GIP is synthesized in and released from enteroendocrine K-cells, the majority of 
which are located in the duodenum and the upper jejunum (Buffa et al. 1975; 
Thomas et al. 1977; Buchan et al. 1978). There are also some endocrine cells 
located in the mucosa of the upper small intestine where GIP and GLP-1 are 
colocalized and presumably secreted simultaneously (Mortensen et al. 2000; 
Mortensen et al. 2003; Theodorakis et al. 2006). However, endocrine cells that 
produce GLP-1 and GIP as well as cells that produce both peptides were found 
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throughout all regions of the rat, porcine and human small intestine (Mortensen et al. 
2003; Theodorakis et al. 2006). Consistent with these findings, GIP mRNA was 
detected in the duodenum and small intestine by RT-PCR analyses and in situ 
hybridization (Usdin et al. 1993). The major secretion stimuli are glucose, few other 
mono- and disaccharides as well as triglycerides (Pederson et al. 1975; Ross & 
Dupre 1978; Cataland et al. 1974; Falko et al. 1975). More precisely, the rate of 
nutrient absorption is the decisive stimulus for GIP secretion. Depending on the 
assay used to measure total versus intact GIP, basal circulating GIP levels in 
humans range between 0.06 and 0.1 nmol/l and rise up to 0.2 - 0.5 nmol/l after a 
meal (Orskov et al. 1996; Vilsboll et al. 2001). Maximal circulating GIP concentrations 
are reached one to three hours after stimulation (Herrmann et al. 1995; Gallwitz et al. 
2006) followed by a gradual decline. However, first rises of GIP are detected 15 
minutes after ingestion of oral glucose or lipids, long before the ingested substrates 
are present in the gut. Therefore an involvement of the vagus nerve in the stimulation 
of GIP was discussed (Meier et al. 2002). This theory is put in doubt by the detection 
of glucokinase expression in the K-cells indicative for a glucose-sensing mechanism 
(Cheung et al. 2000). The half-life of intact biologically active GIP was reported to be 
less than two minutes in rodents (Kieffer et al. 1995) and 7-20 minutes in humans 
(Deacon et al. 2000; Gallwitz et al. 2006). Dipeptidyl peptidase-4 (DPP4) was clearly 
defined to be the primary enzyme responsible for degradation of both incretins by in 
vivo studies performed in humans and rats (Kieffer et al. 1995; Deacon et al. 2000). 
Bioactive peptides with N-terminal penultimate proline or alanine are good substrates 
for DPP-4 (Mentlein 1999). Thus, DPP-4 cleaves bioactive GIP (1-42) at the alanine 
2 position, resulting in the N-terminally truncated biologically inactive GIP (3-42) 
fragment. DPP-4 is present in most vertebrate tissues, including endothelial cells of 
blood vessels and blood plasma (Mentlein 1999) suggesting, that the majority of 
incretin hormones is already inactivated once GIP and GLP-1 have reached portal 
circulation. The kidney was determined to play a major role in the final elimination of 
GIP and GLP-1 as patients suffering from chronic renal insufficiency revealed higher 
plasma GIP (3-42) and GLP-1 (9-36)-amide levels compared to control subjects 
(Meier et al. 2004). Further, GIP clearance was reduced in nephrectomized rats 
(Jorde et al. 1981). DPP-4 exists exceptionally concentrated in the kidney (Mentlein 
1999). Studies in the anesthetized pig, measuring arteriovenous differences of GIP 
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levels across various organ beds, revealed an involvement of the liver and 
extremities besides the kidney in the elimination of exogenous intact GIP (Deacon et 
al. 2001). 
 
2.2.8 The glucose-dependent insulinotropic polypeptide receptor 
 (GIPR) 
The GIP receptor (GIPR) was first cloned from a rat cerebral cortex cDNA library 
(Usdin et al. 1993). Cloning of the hamster (Yasuda et al. 1994), human (Gremlich et 
al. 1995; Yamada et al. 1995; Volz et al. 1995) and mouse (Miyawaki et al. 1999) 
GIPRs followed. The GIPR is a seven transmemebrane domain heterotrimeric G-
protein coupled receptor consisting of three extracellular loops, three intracellular 
loops, an amino-terminal extracellular domain and an intracellular carboxyl terminus 
(Harmar 2001) and belongs to the subfamily B1 of G-protein coupled receptors. This 
group (Kolakowski 1994) also includes receptors like the GLP-1, GLP-2, glucagon, 
VIP, PACAP and GHRH receptor (Harmar 2001). The N-terminal extracellular 
domain extending to amino acid 132 (Gelling et al. 1997b) was found to be essential 
for ligand binding and selectivity, and the third intracellular loop turned out to be 
essential for G-protein coupling (Wheeler et al. 1993; Harmar 2001; Cypess et al. 
1999; Hallbrink et al. 2001; Salapatek et al. 1999; Takhar et al. 1996). The majority of 
the C-terminal domain was found to be dispensable for signaling (Wheeler et al. 
1999). The GIPR exhibits binding specificity for GIP, although some binding of 
Exendin-4, a GLP-1 receptor agonist, was noted at very high concentrations of 1-
10 µM (Gremlich et al. 1995; Wheeler et al. 1993). 
RT-PCR analyses detected mRNA of the GIPR in numerous tissues: pancreas, 
stomach, duodenum, proximal small intestine, fat, adrenal gland, several brain 
regions (telencephalon, diencephalon, brainstem, cerebellum, olfactory bulb and 
pituitary) (Usdin et al. 1993) and bone tissue (Bollag et al. 2000). No mRNA was 
found in spleen and liver tissue. In situ hybridization using tissue sections from adult 
rats as well as rat embryos (embryonic day 12, 17, 19) revealed the presence of 
GIPR mRNA in the pancreas, heart with particularly strong labelling of the cardiac 
endothelium, endothelium of major blood vessels, no clearly defined cells within 
bronchioles, inner layers of the adrenal cortex, adipose tissue and the epithelium of 
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the stomach, small and large intestine. Consistently, GIPR mRNA could not be 
detected in liver and spleen by in situ hybridization as was shown by RT-PCR 
analyses. In addition, in-situ hybridization of numerous brain regions was carried out 
to detect GIPR mRNA reaching the highest intensity in the olfactory bulb, cerebral 
cortex, ventral and dorsal hippocampus, mammilary bodies and the medial part of the 
inferior colliculus (Usdin et al. 1993). 
 
2.2.9 GIPR signal transduction 
GIP potentiates Ca2+-dependent exocytosis of insulin. Binding of GIP to its receptor 
results in activation of a heterotrimeric stimulatory G-protein, followed by adenylate 
cyclase mediated cAMP accumulation and direct inhibition of ATP-dependent 
potassium channels (KATP) which leads to a depolarization of the β-cell membrane 
(Wheeler et al. 1995). Subsequently, mobilization of intracellular Ca2+ stores and 
activation of cell surface voltage-gated calcium channels to allow extracellular Ca2+ 
influx as well as activation of nonselective cation channels lead to an increase of 
intracellular Ca2+ levels (Wheeler et al. 1995). Closure of voltage-dependent (Kv) 
potassium channels and consequent reductions in Kv currents prevent repolarization 
of the β-cell. GIP also acts directly on insulin storage granule exocytosis by activation 
of the cAMP/PKA (protein kinase A) (Ding & Gromada 1997) and the PKA-
independent cAMP/Epac2 modules (Kashima et al. 2001) in addition to 
phospholipase A2 (PLA2) (Ehses et al. 2001), protein kinase B (PKB) (Trumper et al. 
2002; Trumper et al. 2001) and mitogen-activated protein kinase (MAPK) (Ehses et 
al. 2002). Recently, a role of GIP in the regulation of voltage-gated K-channel (Kv) 
expression on the β-cell surface could be identified in vitro and was supposed as a 
possible mechanism of GIP to modulate insulin secretion (Kim et al. 2005a). 
 
2.2.10 Biological actions of GIP 
2.2.10.1 Pancreatic actions of GIP 
The major function of GIP is that of an incretin hormone. Following release from 
enteroendocrine cells (K-cells) in response to nutrient ingestion, GIP binds to its 
specific receptor on the β-cells and enhances glucose-dependent insulin secretion. 
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Initially, potentiation of insulin secretion by GIP was detected in the isolated perfused 
rat pancreas (Pederson & Brown 1978) as well as in dogs (Pederson et al. 1975) and 
humans (Dupre et al. 1973), but a distinct insulinotropic effect of GIP could only be 
observed in the presence of elevated glucose concentrations (Pederson et al. 1975; 
Pederson & Brown 1978; Nauck et al. 1986b). The glucose dependency of the 
insulinotropic GIP effects could be confirmed by stepwise hypo-, eu-, and 
hyperglycemic clamp experiments in combination with the infusion of GIP (Elahi et al. 
1979; Kreymann et al. 1987; Nauck et al. 1993a). Hyperinsulinemia was shown to 
have no impact on GIP-stimulated insulin secretion (Andersen et al. 1978). 
Furthermore, GIP stimulates insulin gene transcription and protein synthesis in the β-
cell (Fehmann et al. 1995; Wang et al. 1996) as well as the expression of 
components of β-cell glucose sensors (Wang et al. 1996). Also, GIP was discussed 
to exhibit proliferative and anti-apoptotic actions on the β-cell (see 2.2.10.2). 
 
2.2.10.2 Proliferative and anti-apoptotic actions of GIP on the β-cell 
As β-cell death is a major contributing factor to diabetes mellitus, an understanding of 
the underlying mechanisms that increase cell survival as well as protect β-cells 
against apoptosis is important. GIP was found to have antiapoptotic as well as 
proliferative functions on the β-cell. In INS-1 cells, GIP was determined to function as 
a mitogenic and anti-apoptotic factor by pleiotropic signaling being dependent on 
glucose metabolism and Ca2+ influx (Trumper et al. 2002; Trumper et al. 2001). In 
this context, pleiotropic stimulation of the mitogenic signaling modules PKA/CREB, 
MAPK and PI3K/PKB mediated by GIP and glucose was shown (Trumper et al. 
2001). In another study, GIP was able to potentiate glucose (11 mM) mediated INS-1 
cell proliferation to levels comparable to GH and GLP-1 (Ehses et al. 2003). It was 
also proposed that GIP is able to reverse caspase-3 activation in INS-1 cells 
mediated by inhibition of long-term p38 MAPK phosphorylation after cells were 
incubated in glucose- and serum-free media in the absence or presence of 
wortmannin (Ehses et al. 2003), an inhibitor of the PI3K/PKB pathway. Moreover, 
GIP was found to reduce apoptosis under glucolipotoxic conditions through down-
regulation of Bax gene transcription via PI3K/PKB-mediated depletion of Foxo1 from 
the nucleus in INS-1 β-cells (Kim et al. 2005b). Similar protective effects of GIP could 
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be detected in wild-type C57BL/6 mouse islets but not in those from GIPR knockout 
(GIPR-/-) mice (Kim et al. 2005b). Recently, GIP was shown to reduce biochemical 
markers associated with endoplasmatic reticulum (ER) stress in INS-1 cells treated 
with thapsigargin, a chemical inducer of ER stress (Yusta et al. 2006). 
Only very limited information is available from in vivo studies. Infusion of GIP via a 
micro-osmotic pump into Vancouver diabetic fatty rats for two weeks, led to down-
regulation of the pro-apoptotic Bax gene and up-regulation of the anti-apoptotic Bcl2 
gene (Kim et al. 2005b). GIPR-/- mice exhibited a paradoxical increase of relative β-
cell area (referring to pancreas area) of ~45% (Pamir et al. 2003), whereas the total 
insulin content of pancreata and insulin mRNA levels in the fed state were 
significantly reduced compared to controls (Pamir et al. 2003). In another study, no 
histological abnormalities were found in the pancreas of GIPR-/- mice (Miyawaki et al. 
1999). Additionally, GIPR-/- mice showed no aberrant glycemic excursions or insulin 
levels in an intraperitoneal glucose tolerance test, which would have pointed to 
changes in islet/β-cell mass (Miyawaki et al. 1999). 
 
2.2.10.3 Extrapancreatic actions of GIP 
2.2.10.3.1 Adipose tissue 
Indicative for a biological function of GIP on adipose tissue is the fact that fat is a 
potent stimulus for GIP secretion in humans (Falko et al. 1975). Also, functional 
GIPRs were found to be expressed on rat adipocytes and 3T3-L1 cells (preadipocyte 
cell line) (Yip et al. 1998) and GIPR mRNA could be detected in adipose tissue 
(Usdin et al. 1993). In vitro studies, using cultured preadipocytes, revealed a dose-
dependent enhancement of lipoprotein lipase activity by GIP (Eckel et al. 1979). 
Additionally, enhancement of insulin-stimulated fatty acid incorporation into 
triglycerides initiated by GIP could be shown in epididymal fat pads (Beck & Max 
1983) and obese Zucker rats (Beck & Max 1987). Moreover, GIP stimulates fatty acid 
synthesis in explants of rat adipose tissue (Oben et al. 1991). Also, inhibitory effects 
of GIP on lipolytic glucagon action were identified in rat adipocytes (Dupre et al. 
1976; Hauner et al. 1988). Interestingly, a high-fat diet did not lead to obesity in 
GIPR-/- mice being indicative for lipolytic effects of GIP (Miyawaki et al. 2002) (see 
2.2.12.1). 
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2.2.10.3.2 Central nervous system 
Findings on GIP expression in the central nervous system are controversial. GIP 
mRNA and protein were identified in the hippocampus (CA1–CA3 region and the 
dentate gyrus (DG), including the granule cell layer (GCL)) of rats by RT-PCR, 
quantitative real-time PCR, in situ hybridization and immunohistochemistry (Nyberg 
et al. 2005) while no GIP mRNA was detected anywhere in the rat brain using in situ 
hybridization (Usdin et al. 1993). GIPR mRNA and protein were observed in the 
hippocampus (Nyberg et al. 2005) as well as in several other brain regions, including 
cerebral cortex and olfactory bulb as was determined using RT-PCR and in situ 
hybridization (Usdin et al. 1993). Chronic intracerebroventricular infusion of GIP 
induced proliferation of hippocampal progenitor cells in rats in vivo as well as of 
adult-derived hippocampal progenitor cells cultured in vitro. This is in line with 
observations of a significantly lower number of newborn cells in the hippocampal 
dentate gyrus of GIPR-/- mice compared to non-transgenic control mice (Nyberg et al. 
2005). Thus, according to the available data GIP might have a regulatory function in 
progenitor cell proliferation within the CNS. 
 
2.2.10.3.3 Bone 
Recently, an influence of GIP on bone tissue was discovered. GIPR mRNA and 
protein were detected by RT-PCR, Western blot analyses and indirect 
immunofluorescence in rat and human normal bone, osteoblast-like cell lines (Bollag 
et al. 2000) as well as in rodent osteoclast cells (Zhong et al. 2007). Application of 
GIP to osteoblast-like cells (SaOS2) resulted in elevated expression of collagen type-
1 mRNA and an increase in alkaline phosphatase activity indicating anabolic actions 
of osteoblast-like cells (Bollag et al. 2000). GIP also increased bone mineral density 
in ovariectomized rats, which is a rodent model for postmenopausal osteoporosis 
(Bollag et al. 2001). Studies in GIPR-/- mice suggested an anabolic effect of GIP on 
bone mass and bone quality (Xie et al. 2005) which was supported by inhibitory 
effects of GIP on bone resorption determined in osteoclasts (Zhong et al. 2007). In 
correspondence to these findings, transgenic mice overexpressing GIP under the 
control of the metallothionein promoter were found to have increased bone mass (Xie 
et al. 2007). In humans, studies of the effects of long-term application of GIP on bone 
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turnover are pending. However, acute application has not shown to alter bone 
turnover in humans (Henriksen et al. 2003). 
 
 
Figure 2.3:  Biological actions of GIP, figure from Baggio 2007. 
 
2.2.11 Incretin hormones in the context of type 2 diabetes mellitus 
In type 2 diabetic patients, the incretin effect was found to be reduced to almost 
absent (Nauck et al. 1986a). Also, a substantial group (~50%) of first-degree relatives 
of type 2 diabetic patients showed a reduced incretin effect compared to control 
subjects but significantly higher GIP effects compared to type 2 diabetic patients in 
hyperglycemic clamp experiments combined with exogenous GIP infusion (Meier et 
al. 2001). In subjects with impaired glucose tolerance, the incretin effect is only 
partially affected (Muscelli et al. 2006). Further studies concentrated on searching for 
the cause leading to the impairment of the incretin effect by evaluation of GIP/GLP-1 
secretion and action. Total and intact GLP-1 secretion were found to be decreased in 
type 2 diabetic patients especially two hours following meal ingestion (Vilsboll et al. 
2001; Toft-Nielsen et al. 2001). According to the fact that the reduction in GLP-1 
secretion of type 2 diabetic patients was relatively small and occurred late (two 
hours) in the response to nutrients, it was concluded that this cannot have a 
significant effect on insulin secretion. This assumption was supported among other 
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things by studies showing that antagonizing exogenous GLP-1 had minor effects on 
insulin secretion in healthy human subjects (Nauck et al. 2004). However, 
insulinotropic action of GLP-1 is vastly preserved in type 2 diabetic patients (Nauck et 
al. 1993) which is especially important for its therapeutic potential. In contrast, the 
insulinotropic action of GIP is greatly reduced to almost absent (Nauck et al. 1993; 
Vilsboll et al. 2002; Krarup et al. 1987; Elahi et al. 1994). Hyper- as well as 
hyposecretion of glucose-dependent insulinotropic polypeptide was found in type 2 
diabetic patients, but most patients seemed to have normal GIP secretion (Vilsboll et 
al. 2001; Toft-Nielsen et al. 2001; Ross et al. 1977). Several mechanisms 
contributing to the reduced insulinotropic action of GIP in type 2 diabetic patients 
have been discussed. Decreased expression of the GIPR in the pancreatic islets was 
found by real-time RT-PCR in association with diminished β-cell response to GIP in 
Zucker diabetic fatty rats, a rodent model of type 2 diabetes (Lynn et al. 2003; Lynn 
et al. 2001). Recently, downregulation of the GIPR and surprisingly to a higher extent 
of the GLP-1 receptor initiated by hyperglycemia (exposition time four weeks) was 
shown in 90% pancreatectomized rats as well as in db/db mice, using 
semiquantitative radioactive multiplex PCR or real time RT-PCR and 
immunostaining. Downregulation of the incretin receptors came along with reduced 
insulin secretion in perifused islets of partially pancreatectomized rats following 
GIP/GLP-1 stimulation (Xu et al. 2007). Additionally, desensitization of the GIPR in 
type 2 diabetic patients was discussed. Such desensitization has been postulated 
due to the loss of insulinotropic activity of GIP after continuous intravenous infusion 
of GIP in rats (Tseng et al. 1996a) and in view of elevated GIP levels found in some 
studies in type 2 diabetic patients (Ross et al. 1977). Up to now this explanation 
seems not likely because no clear evidence of increased GIP levels in type 2 diabetic 
patients exists (Nauck et al. 2004). However, studies by Vilsboll et al., showing a 
relatively preserved incretin effect following a GIP bolus injection but impaired 
insulinotropic action of GIP after long-term GIP infusion (up to 240 minutes) during 
hyperglycemic clamp experiments would suggest underlying desensitization of the 
GIPR (Vilsboll et al. 2002). The presence of inactivating mutations within the exons of 
the GIPR gene was also considered as cause of the reduced insulinotropic effect of 
GIP. Actually, point mutations were found in the GIP receptor gene in human 
populations and some of them affected GIP signaling in cell models. However, it has 
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not been possible to consistently link these mutations to an increased frequency of 
type 2 diabetes (Almind et al. 1998; Kubota et al. 1996). Also, elimination rates of 
intact GIP and its primary metabolite, GIP (3-42), differed not significantly in type 2 
diabetic patients compared to healthy subjects (Vilsboll et al. 2006). Interestingly, in 
human type 2 diabetic patients, a significant increase of L-cells as well as 
enteroendocrine cells containing GLP-1 and GIP but not of K-cells was detected in 
the duodenum compared to controls with normal glucose tolerance (Theodorakis et 
al. 2006). In conclusion, despite great efforts none of the suggested mechanisms 
resulting in a reduced to absent insulinotropic action of GIP has been surely proven 
so far. 
 
2.2.12 Mouse models for studying the functions of the incretin 
 hormone system 
Several mouse models have been established to evaluate the impact of incretin 
hormones in general and in the context of type 2 diabetes mellitus. 
 
2.2.12.1 GIPR knockout mice (GIPR-/-) 
The GIPR-/- mouse was established in 1999 by Miyawaki et al. (Miyawaki et al. 1999) 
on the C57BL/6 background. Knockout (KO) mice developed normally, showed 
normal blood glucose and insulin levels as well as insulin sensitivity in an insulin 
tolerance test but impaired glucose tolerance in an oral glucose tolerance test. No 
difference in glucose and insulin levels of GIPR-/- mice was seen following an 
intraperitoneal glucose tolerance test (IPGTT) compared to controls (Miyawaki et al. 
1999; Hansotia et al. 2004; Pamir et al. 2003). GIPR-/- mice were shown to exhibit a 
paradoxical increase of relative β-cell area (referring to pancreas area) of ~45% 
whereas the total insulin content of pancreata and insulin mRNA levels in the fed 
state were significantly reduced compared to controls. Elsewhere, no histological 
abnormalities were found in the pancreas of GIPR-/- mice (Miyawaki et al. 1999). 
Additionally, GIPR-/- mice showed no changes in islet histology and endocrine cell 
distribution (Pamir et al. 2003). Interestingly, GIPR-/- mice did not develop insulin 
resistance and obesity in response to a high-fat diet fed from 7-50 weeks of age 
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compared to controls. Fat was found to be used as the preferred energy substrate in 
these mice and thus it was not efficiently accumulated in adipocytes (Miyawaki et al. 
2002). 
Recently, female GIPR-/- mice, evaluated between one and five months of age, 
showed that GIP modulates bone growth and bone turnover. GIPR-/- mice revealed 
significantly lower bone mineral density (BMD), bone mineral content (BMC), bone 
area (reflecting bone size), abnormal bone architecture (abnormal trabecular 
structure, decreased trabecular bone volume and bone connectivity) as well as 
impaired biomechanical properties and alterations in bone turnover (alkaline 
phosphatase and osteocalcin, biochemical markers for bone formation, were 
decreased in KO mice) compared to controls. However, reduction in BMD varied 
depending on the skeletal site and the age of the mice and differences became less 
apparent with age. On the basis of these results an anabolic effect of GIP on bone 
mass and bone quality was concluded and it was suggested that GIP might be a 
hormonal link between nutrient ingestion and bone formation (Xie et al. 2005). 
Chronic intracerebroventricular infusion of GIP revealed reduced numbers of new 
proliferating cells in the hippocampal dentate gyrus of GIPR-/- mice leading to the 
assumption that GIP may be involved in neural progenitor cell proliferation (Nyberg et 
al. 2005). Islets from GIPR-/- mice were shown to exhibit increased sensitivity to 
exogenous GLP-1 which is indicative for a compensatory mechanism of the GLP-
1/GLP-1 receptor axis (Pamir et al. 2003). 
 
2.2.12.2 GLP-1 receptor knockout mice (GLP-1R-/-) 
GLP-1 receptor knockout mice revealed impaired glucose tolerance in an oral and 
intraperitoneal glucose tolerance test, being more pronounced in male than in female 
GLP-1R-/- mice. Fasting blood glucose levels were inconsistently elevated in male 
and female GLP-1R-/- mice determined at different age brackets on the CD1 
background (Scrocchi et al. 1996), but turned out to be normal on the C57BL/6 
background (Hansotia et al. 2004). Also, bypassing the incretin effect with an IPGTT 
led to elevated blood glucose levels, but not in all studies to reduced insulin levels of 
GLP-1R-/- mice (Hansotia et al. 2004; Scrocchi et al. 1996; Preitner et al. 2004). No 
changes in total β-cell volume and numbers were found and the insulin and glucagon 
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content of the pancreas were similar compared to controls. However, alterations in 
islet topography with α–cells being more centrally located than in controls and 
reduced formation of large β-cell clusters were determined in KO mice compared to 
controls (Ling et al. 2001). Despite evidence that GLP-1 is a potent inhibitor of short-
term food intake, GLP-1 mice exhibit normal body weight and food intake (Scrocchi 
et al. 1996). The search for compensatory mechanisms of the GIP/GIPR axis in GLP-
1R-/- knockout mice revealed increased GIP levels following oral glucose challenge 
as well as increased GIP stimulated insulin release from the perfused pancreas or 
isolated islets (Flamez et al. 1999; Pederson et al. 1998). 
 
2.2.12.3 Double incretin receptor knockout mice (DIRKO) 
Double incretin receptor knockout mice (DIRKO) lacking both a functional GIPR and 
a functional GLP-1R were found to exhibit more severe glucose intolerance than the 
individual mutants following oral glucose challenge. Similar to mice lacking a 
functional GLP-1 receptor, DIRKO mice exhibited abnormal glycemic excursions after 
an intraperitoneal glucose load. As in single incretin receptor knockout mice (SIRKO) 
mice, insulin sensitivity was unchanged compared to controls. Total pancreatic 
insulin content in the fasted state was normal and no apparent difference in the 
number and size of islets was seen compared to controls. Also, no differences were 
detected in growth, but DIRKO mice revealed increased food intake over a 24-h time 
period compared to control mice. Thus, disruption of both incretin receptors did not 
result in an overt diabetic phenotype indicated by normal fasting blood glucose levels 
(Hansotia et al. 2004; Preitner et al. 2004). 
 
2.2.12.4 GIPRdn transgenic mice 
GIPRdn transgenic mice expressing a dominant-negative GIPR under the control of 
the rat insulin 2 promoter show an overt diabetic phenotype due to a disturbed 
development of the endocrine pancreas. As early as three weeks of age, transgenic 
mice reveal severe glucosuria and hyperglycemia coming along with severe 
hypoinsulinemia from 30 days of age onwards. Immunohistochemical staining of the 
four principal islet cell hormones (insulin, glucagon, somatostatin, pancreatic 
polypeptide) revealed marked alterations of islet composition, namely a shift towards 
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cells expressing glucagon and somatostatin. Quantitative stereological analyses of 
the endocrine pancreas demonstrated severe reduction of total islet and total β-cell 
volumes within the pancreas first detected in 10-day-old animals and showing a 
progressive character with increasing age. In addition, the total volume of isolated β-
cells (single β-cells and small β-cell clusters) turned out to be significantly reduced in 
GIPRdn transgenic mice compared to controls, indicative for disturbed islet 
neogenesis (Herbach et al. 2005). Additionally, alterations in the kidney including 
renal and glomerular hypertrophy, glomerulosclerosis and tubulo-interstitial changes 
could be detected (Herbach 2002). 
 
2.2.12.5 Glucose-dependent insulinotropic polypeptide transgenic mice 
Transgenic mice overexpressing GIP under the control of a heavy-metal inducible 
mouse metallothionein promoter (Palmiter et al. 1993) were created to examine the 
effect of GIP overexpression on the skeleton. RT-PCR analyses revealed high GIP 
expression in multiple tissues, including lung, liver, kidney, intestine and pancreas, 
with significant but lower expression in the brain and the heart. GIP transgenic mice 
showed a significant increase in markers of bone formation (elevated osteocalcin 
levels) and a decrease in markers of bone resorption (decreased levels of 
pyridinoline crosslinks). In addition, significantly increased bone mass (bone mineral 
content and bone mineral density) as measured by densitometry and 
histomorphometry could be determined which is consistent with the biochemical data. 
GIP transgenic mice were found to have normal serum glucose and insulin levels 
(Xie et al. 2007). Evaluations on behaviour of GIP transgenic mice revealed that the 
GIP receptor plays a role in the regulation of locomotor activity and exploration (Ding 
et al. 2006). 
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2.3 The pig as an animal model in diabetes research 
Currently, pig animal models represent only a minor fraction in biomedical research. 
For this purpose rodentiae (mice/rats) as well as lagomorphae (rabbits) are used 
(Bundesministerium für Ernährung, 2006). Readily achievable animal welfare, high 
cost effectiveness and good standardization of experimentation argue for the usage 
of these small animal species. However, experimentation results obtained from these 
small animal models may not always mimic the human conditions faithfully enough. 
In contrast, a pig model has numerous advantages compared to rodent models. First, 
a great advantage is the size of the pig, allowing the imaging of internal vessels and 
organs using standard imaging techniques in human medicine as well as the 
collection of larger blood volumes in order to perform studies similar to those 
accomplished in humans. A pig animal model also warrants sufficient tissue for 
sample collection post-mortem. Moreover, pigs can be trained. This allows the 
performance of tests in conscious, unstressed animals as well as tests in relation to 
ingestion of meals like an oral glucose tolerance test. 
 
2.3.1 Compatibilities between humans and pigs 
Most importantly, many of the pig’s organ systems, as well as physiological and 
pathophysiological responses resemble those of the human. 
Pigs and humans have a high degree of similarity of the skin and subcutaneous 
tissue (Benech-Kieffer et al. 2000; Meyer 1996; Qvist et al. 2000) which is especially 
interesting for subcutaneous drug administration like insulin administration in diabetic 
patients. The morphology and physiology of the digestive system of the omnivores 
pig and human are much alike. Both of them are highly dependent on dietary quality 
because symbiotic microorganisms play a minor role in modifying ingested nutrients 
(Miller & Ullrey 1987). Ingesta transit times and digestive effectiveness are 
comparable (Miller & Ullrey 1987). The porcine pancreas resembles the human 
pancreas in size, shape and position. Islets from adult pigs are more similar to adult 
human islets because islet structure in young pigs is more diffuse and the reticular 
capsule separating endocrine from exocrine tissue is less evident than in humans 
(Wieczorek et al. 1998; van Deijnen et al. 1992; Ulrichs et al. 1995). Of all types of 
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experimental xenotransplantations, porcine islet transplantation was estimated to be 
the closest to clinical application on a large scale. Clinical trials have already been 
reported (Rood & Cooper 2006). Interestingly, islet amyloid polypeptide (IAPP) is 
expressed predominantly in β-cells but also in some α- and δ-cells in pigs and in 
humans (Lukinius et al. 1996). In contrast to humans, pigs are not prone to form 
pancreatic amyloid plaques (Larsen & Rolin 2004). Pig and human islets show similar 
sensitivity to damage induced by hydrogen peroxide, nitric oxide and superoxide, but 
are more resistant than rat islets (Wacker et al. 1995). Porcine and human insulin 
differ by only one amino acid at position 30 of the B-chain. Porcine insulin has even 
been used for almost 80 years to treat human diabetes (Bromberg & LeRoith 2006). 
Also blood glucose levels of pigs and humans range within similar limits (pig: 70 – 
115 mg/dl; human: 65 – 100 mg/dl) (Kraft 1999; Swindle 2007). Human GIP amino 
acid sequence differs from porcine GIP only at residues 18 (human: His Æ porcine: 
Arg) and 34 (human: Asn Æ porcine: Ser) (Moody et al. 1984; Jornvall et al. 1981), 
while the GLP-1 amino acid sequence is fully conserved in both species (Orskov 
1992). Porcine GIP has already been used in numerous human studies (Krarup et al. 
1987; Jones et al. 1987; Amland et al. 1985). 
 
2.3.2 Pig animal models of diabetes mellitus 
Pig animal models of diabetes mellitus developed either spontaneously or have been 
generated by selective breeding or chemical induction. 
In the 1970s two lines of Yucatan minipigs with altered glucose tolerance (one line 
with enhanced and one line with impaired glucose tolerance) were established by 
selective breeding. Females of the strain with impaired glucose tolerance rapidly 
became obese and some developed insulin resistance and diabetes. However, 
glucose intolerance was not detected in the F7 generation making these pigs 
currently not available for further investigations (Phillips et al. 1982). Male Göttingen 
minipigs fed a high-fat high-energy diet became obese (increased weight and body 
fat) and developed increased blood glucose and insulin levels (Larsen et al. 2001) 
while female pigs became obese and revealed increased insulin secretion, following 
an intravenous glucose tolerance test (Johansen et al. 2001). Chineze Guizhou 
minipigs fed a high-fed high-sucrose diet for six months revealed elevated blood 
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glucose levels, decreased insulin sensitivity, impaired glucose tolerance as well as 
increased levels of total cholesterol, triglycerides, free fatty acids and serum TNFα/β 
without chemical destruction of the islets. Also, atherosclerotic lesions were present 
in the aorta of these pigs (Xi et al. 2004). Osabaw pigs which lived in genetic isolation 
for a long time are generally considered obese. Obesity is considered a risk factor for 
the development of type 2 diabetes. Fed a high-fat high-cholesterol diet, pigs exhibit 
more severe obesity, but also insulin resistance, glucose intolerance, dyslipidemia 
and hypertension and are considered as a model for the human metabolic syndrome 
(Dyson et al. 2006). Familial hypercholesterolemic pigs, carrying a missense 
mutation within the low density lipoprotein (LDL) receptor, which is inherited in an 
autosomal fashion, were reported to show hypercholesterolemia and develop severe 
coronary and abdominal aortic atherosclerosis, while being fed a low fat pig diet 
(Prescott et al. 1991; Prescott et al. 1995). 
Chemical induction of diabetes in pigs is still the primary means. For this purpose, 
substances like Streptozotocin (STZ) and Alloxan are available. STZ induces DNA 
strand breaks and subsequently activates repair mechanisms that result in a 
reduction of cellular Nicotinamide Adenine Dinucleotide (NAD) and ATP-levels below 
physiological levels, which leads to β-cell death. The mechanism of action of alloxan 
is similar (Yamamoto et al. 1981). These substances have been used in several pig 
breeds. For example Sinclair minipigs, treated with alloxan and fed an atherogenic 
diet developed dyslipidemia and atherosclerotic lesions in the carotid artery (Dixon et 
al. 1999). Göttingen minipigs treated either with STZ or Alloxan in combination with 
nicotinamide which partially protects the islets, are considered to be a good model for 
studying the pathophysiology and agents for treatment of diabetes (Larsen et al. 
2003; Kjems et al. 2001). 
Thus, there are already several pig models available, showing metabolic 
abnormalities as they are present in human type 2 or type 1 diabetic patients as well 
as cardiovascular complications. Considering cardiovascular complications, it is 
especially useful that pigs develop coronary, aortic, iliac and carotid atherosclerosis 
in anatomical locations relevant to the human condition also recapitulating the 
histopathology seen in humans namely proliferative lesions consisting of smooth 
muscle cells, macrophages, lymphocytes, foam cells, calcification, fibrous caps, 
necrotic and apoptotic cells, plaque hemorrhage and expanded extracellular matrices 
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(Prescott et al. 1991; Prescott et al. 1995; Brodala et al. 2005; Hasler-Rapacz et al. 
1994; Gerrity et al. 2001; Nichols et al. 1992). 
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3 Animals, Materials and Methods 
3.1 Pigs 
Pigs were housed under conventional conditions on a planar-fixed basement with 
straw litter. Animals were fed a commercial diet once daily. Water was offered ad 
libitum. All animals investigated in this study were hemizygous male and female 
transgenic pigs and non-transgenic littermate control animals. During all study 
procedures, animals were housed in single pens under controlled conditions. Animals 
were trained carefully in all experimental procedures before the start of experiments. 
All animal experiments were carried out according to the German Animal Protection 
Law (209.1/211-2531-54/02). 
 
Table 3.1:  Composition of the different diets 
Deuka primo care was fed to piglets up to 25 kg; deuka porfina U was fed to growing 
and adult sows and boars; ME: metabolizable energy 
 
  Deuka primo care Deuka porfina U 
MJ ME/kg 14.0 12.6 
Crude protein % 16.0 17.0 
Crude fat % 4.3 3.0 
Crude fiber % 4.5 6.5 
Crude ash % 4.6 5.5 
Lysin % 1.35 0.9 
Calcium % 0.65 0.85 
Phosphorus % 0.55 0.55 
Sodium % 0.2 0.2 
 
3.2 Material 
3.2.1 Apparatuses 
Accu-jet® pro pipette controller Brand, Wertheim 
Analytical balance Sartorius, Göttingen 
AU 400 autoanalyzer  Olympus, Hamburg 
Multipette®  plus Eppendorf, Hamburg 
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Axiovert 135 microscope Zeiss, Oberkochen  
Benchtop 96 tube working rack Stratagene, La Jolla, USA 
Incubator Heraeus, Munich 
Staining box according to Schiefferdecker  Roth, Karlsruhe 
Glass case for glass rack Roth, Karlsruhe 
Agarose gel electrophoresis chamber  MWG-Biotech, Ebersberg 
HM 315 microtome  Microm, Walldorf 
Heating plate with magnetic stirrer IKA process equipment, Staufen 
Hitachi 911 autoanalyzer Roche, Mannheim  
Hybridization oven  H. Saur, Reutlingen 
Gel documentation system  Intas, Göttingen 
Labotec thermo-cell-transporter Labotec, Bovenden-Göttingen  
Microwave Siemens, Munich 
MS1 Minishaker  IKA process equipment, Staufen 
NanoDrop-1000 spectrophotometer  NanoDrop Technologies,  
  Wilmington, USA 
pH-meter WTW, Weilheim 
Power Pac 300 Bio Rad, Munich 
Precision® XceedTM Glucometer  Abbott, Wiesbaden 
Phosphorimager Storm 860  GE Healthcare, Munich 
Scintillation counter LS6500  Beckman, Palo Alto, USA 
Thermomixer 5436  Eppendorf, Hamburg 
UV-Crosslinker Biometra, Göttingen 
LB 2111 γ-counter Berthold, Bad Wildbad 
Videoplan® image analysis system  Zeiss-Kontron, Eching 
 
Thermocycler: 
Biometra Uno Thermoblock  Biometra, Göttingen 
Biometra TProfessional Biometra, Göttingen 
Mastercycler® gradient  Eppendorf, Hamburg 
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Centrifuges: 
Heraeus Megafuge 1.0R Heraeus, Munich 
Rotanta 96 Hettich, Tuttlingen 
Table centrifuge with cooling (5417R)  Eppendorf, Hamburg 
 
3.2.2 Consumables 
Cavafix® Certo® central venous catheter B. Braun, Melsungen 
Centrifuge tubes (15 ml, 50 ml) Falcon®, Becton Dickinson, 
  Heidelberg 
Culture flasks with filter Nunc, Wiesbaden 
Culture dishes (diameter 10 cm) Nunc, Wiesbaden 
Disposable syringes (2, 5, 10, 20 ml) Codan Medical ApS, Roedby, 
  Denmark 
Disposable tubes for γ-counter Sarstedt, Nümbrecht 
Disposable plastic pipettes Falcon®, Becton Dickinson, 
  Heidelberg 
Uni-Link embedding cassettes Engelbrecht, Edermünde 
Hybond-N+ Nylon membrane GE Healthcare, Munich 
MicroSpinTM S-300 HR Columns GE Healthcare, Munich 
MillexTM-GP syringe driven filter unit® 
(0.22 µm) Millipore, Billerica, USA 
Monovette® blood collection system 
(Serum, EDTA) Sarstedt, Nümbrecht 
Multi-well plates for cell culture Greiner bio-one, Frickenhausen 
OP-Cover (60 x 90 cm) A. Albrecht, Aulendorf 
Parafilm® M American Can Company,  
  Greenwich, USA 
PCR reaction tubes (0.2 ml) G. Kisker GbR, Steinfurt 
Perfusor® cable (50 cm) B. Braun, Melsungen 
Precision XtraTM Plus blood glucose 
stripes  Abbott, Wiesbaden 
Safe-Lock reaction tubes (1.5 ml, 2 ml) Eppendorf, Hamburg 
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Skin adhesive spray A. Albrecht, Aulendorf 
Sterican® cannulas (18 G, 20 G) B. Braun, Melsungen 
3-way-Stopcock Fresenius Kabi, Bad Homburg 
Storage phosphor screen Bio Rad, Munich 
Vasco® OP Protect gloves B. Braun, Melsungen 
Vascocan® indwelling venous catheter B. Braun, Melsungen 
Vicryl (2-0) suture material Ethicon, Norderstedt 
 
3.2.3 Chemicals 
Comment: unless otherwise noted, all chemicals were used in p.a. quality 
 
Acetic acid (glacial acetic acid)  Roth, Karlsruhe 
Agar, granulated Difco, Detroit, USA 
Agarose Invitrogen, Karlsruhe 
Ampicillin  AppliChem, Darmstadt 
Bacto™ Trypton  BD, Heidelberg 
Bacto™ Yeast Extract  Difco, Detroit, USA 
Bromophenolblue Serva, Heidelberg 
Chloroform  Merck, Darmstadt 
DEPC (Diethylpyrocarbonate)  Sigma, Deisenhofen 
3,3´ diaminobenzidine tetrahydrochloride KemEnTec, Copenhagen, 
  Denmark 
DTT (100 mM)  Invitrogen, Karlsruhe 
EDTA   Merck, Darmstadt 
Ethanol  Roth, Karlsruhe 
Ethidiumbromide (solution: 1 %)  Merck, Darmstadt 
Formaldehyde solution, 37% Sigma-Aldrich, Deisenhofen 
D-(+)-glucose Sigma-Aldrich, Deisenhofen 
Disodiumhydrogenphosphate Merck, Darmstadt 
Glucose 50% solution B. Braun, Melsungen 
Glycerine Roth, Karlsruhe 
Hydrochloric acid (1 N) Merck, Darmstadt 
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Hydrochloric acid (25%) Merck, Darmstadt 
Hydrogen peroxide 35% Roth, Karlsruhe 
Kalium chloride  Merck, Darmstadt 
Kaliumdihydrogenphosphate  Merck, Darmstadt 
Magnesium chloride (25 mM) Qiagen, Hilden 
Magnesium chloride Merck, Darmstadt 
Magnesium sulphate Merck, Darmstadt 
0.9% NaCl solution B. Braun, Melsungen 
2-Propanol  Merck, Darmstadt 
Spermidine  Sigma, Deisenhofen 
Sodiumacetate-trihydrate Merck, Darmstadt 
Sodium chloride Merck, Darmstadt 
Sodiumdodecylsulphate Merck, Darmstadt 
Sodium hydroxide Roth, Karlsruhe 
Tris-(hydroxymethyl)-aminomethane Roth, Karlsruhe 
X-gal (5-bromo-4-chloro-3-indolyl-β-D-galactoside)  Invitrogen, Karlsruhe 
Xylol  SAV LP, Flintsbach a. Inn 
 
3.2.4 Antibodies, drugs, enzymes and other reagents 
3.2.4.1 Antibodies 
Polyclonal guinea pig anti-porcine insulin Dako Cytomation, Hamburg 
HP conjugated polyclonal rabbit anti-guinea pig IgG Dako Cytomation, Hamburg 
 
3.2.4.2 Drugs 
Altrenogest (Regumate®) Serumwerk Bernburg, Bernburg 
Cefquinom (Cobactan®) Intervet, Unterschleißheim 
Glucagon (GlucaGen®) Novo Nordisk, Mainz 
hCG (Ovogest®) Intervet, Unterschleißheim 
Heparin-Sodium (25.000 IE/5 ml) B. Braun, Melsungen 
Ketamine hydrochloride (Ursotamin®) Serumwerk Bernburg, Bernburg 
Metamizol-Sodium (Vetalgin®) Intervet, Unterschleißheim 
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PMSG (Intergonan®) Intervet, Unterschleißheim 
Xylazine (Xylazin 2%) WDT, Garbsen 
 
3.2.4.3 Enzymes 
DNase I (10 U/µl) Roche, Mannheim 
Proteinase K (20 mg/ml)  Roche, Mannheim 
Herculase® enhanced DNA Polymerase Stratagene, La Jolla, USA 
HotStar Taq Polymerase (5 U/µl) Qiagen, Hilden 
Restriction enzymes and -buffers Fermentas, St. Leon Roth 
Restriction enzymes and -buffers New England Biolabs, Boston, 
  USA 
RNase-Inhibitor (20 U/µl) Applied Biosystems, Foster City, 
 USA 
Ribonuclease A (RNase-A) (0.2 U/µl) Roche, Mannheim 
Superscript™ II Reverse Transcriptase (200 U/µl) Invitrogen, Karlsruhe 
Taq Polymerase (5 U/ml) Qiagen, Hilden 
T4 DNA Ligase (2000 U/µl) MBI Fermentas, St. Leon Rot 
 
3.2.4.4 Other reagents 
α-[32P]-dCTP GE Healthcare, Munich 
Blood & Cell Culture DNA Midi Kit Qiagen, Hilden 
dNTPs (dATP, dCTP, dGTP, dTTP)  MBI Fermentas, St. Leon Roth 
Eukitt® Electron Microscopy Sciences, 
  Hatfield, USA 
5 x first strand buffer Invitrogen, Karlsruhe 
Gel blotting paper (GB002) (Whatman-paper) Schleicher & Schüll, Dassel 
Gentamycine sulphate Sigma-Aldrich, Deisenhofen 
Jetquick Gel extraction Spin Kit Genomed, Löhne 
Lamb serum Invitrogen, Karlsruhe 
10 x ligation buffer MBI Fermentas, St. Leon Roth 
Linear acrylamide (5 mg/ml) Ambion, Austin, USA 
10 x PCR buffer Qiagen, Hilden 
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Porcine Insulin RIA Kit Millipore, Billerica, USA 
Porcine serum Dako Cytomation, Hamburg 
Q-solution Qiagen, Hilden 
QIAquick® Spin Miniprep Kit Qiagen, Hilden 
Rabbit serum MP Biomedicals, Illkirch, France 
Random Primers (3 mg/µl) Invitrogen, Karlsruhe 
Rapid-Hyb buffer  GE Healthcare, Munich 
Synthetic porcine GIP Bachem, Weil am Rhein 
Synthetic Exendin-4 Bachem, Weil am Rhein 
TOP 10 chemically competent E.coli Invitrogen, Karlsruhe 
TRIZOL Reagent  Invitrogen, Karlsruhe 
Vet-Sept® solution (10%) A. Albrecht, Aulendorf 
Wizard® Genomic DNA Purification Kit Promega, Mannheim 
 
3.2.5 Buffers, media and solutions 
Comment: unless otherwise noted, in a Millipore machine de-ionized water was used 
as solvent which is termed aqua bidest. 
 
3.2.5.1 DEPC water (0,1 % (v/v)) 
Dissolve 1 ml DEPC in 1000 ml aqua bidest. overnight while stirring. For inactivation 
of DEPC autoclave at least three times. Storage at room temperature. 
 
3.2.5.2 DNaseI buffer 
10 mM  Tris 
10 mM MgCl2
pH 7.4 
3.2.5.3 PBS buffer 
137 mM NaCl 
10 mM Na2HPO4 
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2.7 mM KCl 
2 mM KH2PO4
3.2.5.4 Proteinase-K solution 
20 mg Proteinase K 
1 ml  Aqua bidest. 
Aliquotet; storage at -20°C 
3.2.5.5 TBS buffer (10 x) 
90 g NaCl 
60.5 g Tris 
ad 1000 ml Aqua bidest. 
pH 7.6 
3.2.5.6 TE-buffer 
10 mM  Tris/HCl (pH 8.0) 
1 mM  EDTA (pH 8.0) 
 
3.2.5.7 Buffers for agarose gels 
3.2.5.7.1  TAE buffer (50 x) 
242 g Tris 
57.1 ml glacial acetic acid 
100 ml  EDTA 0.5 M (pH 8.0) 
ad 1000 ml Aqua bidest. 
3.2.5.7.2  TAE running buffer (1 x) 
20 ml 50 x TAE buffer 
ad 1000 ml  Aqua bidest. 
3.2.5.7.3  Loading buffer for DNA (6 x) 
3 ml glycerine 
7 ml aqua bidest. 
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1 point of a 
spatula bromophenolblue 
Aliquotet, storage at -20°C 
 
3.2.5.8 Solutions for Southern blotting 
3.2.5.8.1  Denaturation solution 
0.5 M NaOH 
1.5 M NaCl 
3.2.5.8.2  Neutralization solution 
1 M  NaCl 
0.5 M Tris/HCl (pH 8.0) 
3.2.5.8.3  SSC buffer (20 x) 
3 M  NaCl 
0.3 M  Sodiumacetate-trihydrate 
pH 7.0 
3.2.5.8.4  Washing solution I 
2 x  SSC 
0.1% SDS 
3.2.5.8.5  Washing solution II 
1 x SSC 
0.1% SDS 
 
3.2.5.9 Solutions for bacterial culture 
3.2.5.9.1  Luria-Bertani (LB)-medium 
10 g bacto trypton 
5 g bacto yeast extract 
10 g NaCl 
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ad 1000 ml Aqua bidest. 
pH 7.0 (adjust with 5 M NaOH) 
Autoclave, storage at room temperature 
3.2.5.9.2  SOC medium 
2% bacto trypton 
0.5% bacto yeast extract 
0.05% NaCl 
10 mM MgCl2 
10 mM MgSO4 
0.4% glucose 
MgCl2, MgSO4 and glucose were added after autoclaving 
3.2.5.9.3  Agar-LB-plates 
1000 ml LB-medium 
15 g agar, granulated 
After autoclaving solution was cooled down to 50°C under constant stirring on a 
magnetic stirrer before ampicillin (100 µg/ml) was added. Then the solution was 
effused in 90 mm petri dishes. Petri dishes were stored at 4°C overarm after 
hardening of the agar. 
 
3.2.6 Oligonucleotides 
RIP2 (sense): 5’-TAGTCGACCCCCAACCACTCCAAGTGGAG-3’ 
RIP2 (antisense): 5’-CAGCCCTAACTCTAGACTCGAGGGATCCTA-3’ 
GIPRdn (sense): 5’-TTTTTATCCGCATTCTTACACGG-3’ 
GIPRdn (antisense): 5’-ATCTTCCTCAGCTCCTTCCAGG-3’ 
Actin (sense): 5’-TGGACTTCGAGCAGAGATGG-3’ 
Actin (antisense): 5’-CCTCTACGCCAACACGGTG-3’ 
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3.2.7 DNA molecular weight markers 
Gene RulerTM (1 kb DNA Ladder)  MBI Fermentas, St. Leon Roth 
Lambda DNA/EcoRI + HindIII-Marker MBI Fermentas, St. Leon Roth 
pUC Mix Marker 8  MBI Fermentas, St. Leon Roth 
 
3.3 Methods 
3.3.1 Generation of the RIP2-GIPRdn expression vector 
3.3.1.1 Restriction digest 
The utilized amount of DNA was incubated together with the restriction 
endonuclease, its recommended buffer at the recommended temperature for 90 
minutes in a total volume of 20 µl. Usually, 10 units of the enzyme per µg DNA were 
used. 
 
3.3.1.2 Ligation of DNA fragments 
Ligation means the connection of the 3’ hydroxy-end and the 5’ phosphorus-end of a 
nucleic acid using an enzyme called ligase. Here, 100 ng vector DNA were incubated 
with a two to three times molar overage of insert DNA in a total volume of 20 µl 
together with 2 µl of T4 DNA Ligase and 2 µl 10 x ligation buffer for two hours at RT. 
The required amount of insert DNA was calculated as follows: 
 
          ng vector * kb-size insert * molar (vector : insert) DNA ratio 
Insert (ng) =    ------------------------------------------------------------------------------------  
          kb-size of the vector 
 
3.3.1.3 Transformation of E. coli 
A 100-µl aliquot of transformation-competent E. coli TOP10-cells stored at -80°C was 
slowly thawed. 1 µg of plasmid DNA or up to 10 µl of a ligation batch was added to 
the bacteria solution, gently mixed and incubated on ice for 30 minutes. After that, a 
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heat shock was applied for exactly 45 seconds followed by an incubation step of 2-3 
minutes on ice. Subsequently, 800 µl of SOC medium (without antibiotics) were 
added to the transformation batch and the mix was incubated at 37°C for one hour on 
a thermoblock. The transformed bacteria were then plated with a bended sterile 
pasteur glass-pipette on agar-LB-plates (+ 50 µg/ml ampicillin) and incubated at 37°C 
overnight. After twelve to sixteen hours of incubation single colonies were visible. 
 
3.3.1.4 Isolation of plasmid DNA from E. coli 
Single colonies were picked with a sterile pipette tip and transferred in 3 ml of 
ampicillin containing LB-medium. Following incubation at 37°C for 8-10 hours on a 
shaking incubator, bacteria containing medium was centrifuged at 20,800 x g and 
4°C for 10 minutes. Isolation of plasmid DNA was carried out using the QIAquick® 
Spin Miniprep Kit according to the manufacturer’s instructions. 
 
3.3.2 Lentiviral construct 
The expression cassette consisting of the rat insulin 2 gene promoter (RIP2) and the 
cDNA of a human dominant-negative glucose-dependent insulinotropic polypeptide 
receptor (hGIPRdn) was described previously (Herbach et al. 2005). The construct 
was cloned into the lentiviral vector LV-pGFP (Pfeifer et al. 2002) via the ClaI and 
SalI restriction sites by Prof. A. Pfeifer and coworkers (Institute of Pharmacology and 
Toxicology, University of Bonn, Germany; Figure 3.1). Recombinant lentivirus was 
produced by Prof. A. Pfeifer and coworkers as previously described (Pfeifer et al. 
2002). 
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Figure 3.1:  Lentiviral construct 
The lentiviral vector (LV-GIPRdn) carrying the cDNA of the human dominant-negative GIP-
receptor (hGIPRdn) under the control of the rat insulin 2 gene promoter (RIP2); LTR: long 
terminal repeat; ppt: polypurine tract; W: woodchuck hepatitis posttranscriptional regulatory 
element; wavy lines: pig genome; SIN: self-inactivating mutation. 
 
3.3.3 Generation of transgenic animals 
3.3.3.1 Zygote collection and injection of the lentiviral construct 
Gilts, 6-7 months of age, were used as zygote donors. Superovulation was 
performed by an intramuscular injection of 1200 IU of pregnant mare serum 
gonadotropin (PMSG) (Intergonan®, Intervet) and 72 hours later ovulation was 
stimulated by an intramuscular injection of 750 IU of human chorionic gonadotropin 
(hCG) (Ovogest®, Intervet). Twenty-four and 36 hours after hCG injection, donors 
were artificially inseminated with 3x109 sperms of a German Landrace boar 
suspended in 100 ml of a commercial BTS extender (Beltsville). Thirty-two to 34 
hours after the first insemination, donor gilts were slaughtered and genital tracts were 
collected. After transport to the laboratory in a 37°C temperated box (Labotec 
thermo-cell-transporter, Labotec), corpora lutea were counted and oviducts were 
flushed into a polystyrene culture dish (diameter 10 cm, Nunc). The flushing medium 
consisted of PBS supplemented with 20% heat-inactivated lamb serum (Invitrogen) 
and 50 mg/l gentamicin sulphate (Sigma-Aldrich). Zygotes were collected followed by 
subzonal virus injection into the perivitelline space under an inverted microscope 
(Axiovert 135, Zeiss) using glass capillaries. Embryo transfer was performed the 
same day. 
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3.3.3.2 Embryo transfer 
Six-month-old German Landrace gilts were used as recipients. Synchronization by 
oral administration of altrenogest (Regumate®, Serumwerk Bernburg) over a 15-day 
period was followed by administration of 750 IU PMSG. Ovulation was induced 72 
hours later with 750 IU hCG. Embryo transfers were performed laparoscopically 
according to the procedure of Besenfelder et al. (Besenfelder et al. 1997) under 
general anesthesia using a combination of 2 ml per 10 kg body weight (BW) 
ketamine hydrochloride (Ursotamin®, Serumwerk Bernburg) and 0.5 ml per 10 kg 
xylazine (Xylazin 2%, WDT) injected intravenously. Thirty to 50 injected embryos 
were transferred into one oviduct of each recipient. Twenty-one to 25 days after the 
transfer, recipients were checked ultrasonographically for pregnancy. 
 
3.3.4 Identification of transgenic animals 
GIPRdn transgenic pigs were identified by PCR as well as by Southern blot analysis. 
Thereby Southern blot analysis served not only for discrimination of transgenic pigs 
from wild-type animals, but also for determination of the number of integration sites of 
the transgene as well as determination of different integration sites. 
 
3.3.4.1 Polymerase chain reaction (PCR) 
3.3.4.1.1 Isolation of genomic DNA from ear punches 
Ear punches were obtained from 2-day-old piglets and stored at –20°C until further 
processing. For isolation of genomic DNA the Wizard DNA Extraction Kit® (Promega) 
was used according to the manufacturer’s instructions. In brief, ear punches, 3-5 mm 
in diameter, were transferred into 1.5 ml reaction tubes and incubated overnight at 
55°C on a shaker after addition of the following mastermix: 
 
Mastermix: 120 µl 0.5 M EDTA pH 8.0 
 500 µl Nuclei Lysis Solution 
 17.5 µl Proteinase K 
 
 44
Animals, Materials and Methods 
The following day samples were centrifuged at 14,000 x g, 20°C to remove 
undigested constituents and the supernatant was transferred in new 1.5-ml reaction 
tubes. RNA removal was accomplished by addition of RNase-A. For protein 
precipitation, 200 µl protein precipitation solution were added followed by a 
centrifugation step. Afterwards DNA precipitation was carried out with 600 µl 
isopropanol and the DNA pellet was washed twice with 70% ethanol. Then the pellet 
was air-dried, resuspended in 50-100 µl DNA rehydration solution and incubated at 
65°C on a shaker for one hour. To ensure that DNA has totally dissolved, DNA was 
stored at 4°C overnight. 
The next day, DNA concentration was measured using a NanoDrop-1000 
spectrophotometer (NanoDrop Technologies) and the concentration was adjusted to 
100 ng/µl for PCR use. 
 
3.3.4.1.2 PCR conditions 
For identification of GIPRdn transgenic pigs the following transgene-specific primers 
were used:  
RIP2 (sense):  5’-TAGTCGACCCCCAACCACTCCAAGTGGAG-3’ 
RIP2 (antisense): 5’-CAGCCCTAACTCTAGACTCGAGGGATCCTA-3’ 
The amplification of so-called house-keeping genes which are being expressed 
independently of cell type, cell cycle or external influences serves as proof for the 
integrity of the isolated genomic DNA. Here, the β-actin gene was chosen and the 
following gene-specific primers were used: 
β-actin (sense):  5’-TGGACTTCGAGCAGAGATGG-3’ 
β-actin (antisense): 5’-CCTCTACGCCAACACGGTG-3’ 
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The PCR reactions with a total volume of 20 µl were prepared on ice in 0.2-µl 
reaction tubes as follows: 
 
Table 3.2:  Reaction batch RIP2-hGIPRdn PCR 
 
 RIP2-hGIPRdn
10 x buffer (Qiagen) 2 µl 
MgCl2 (25 mM) (Qiagen) 1.25 µl 
dNTPs (1 mM) 2 µl 
Sense Primer (2 µM) 2 µl 
Antisense Primer (2 µM) 2 µl 
HotStar Taq DNA Polymerase 
(5 U/µl) (Qiagen) 
0.1 µl 
Aqua bidest. 9.65 µl 
Template (100 ng/µl) 1 µl 
Total volume 20 µl 
 
Table 3.3:  Reaction batch β-actin PCR 
 
 β-actin 
10 x buffer (Qiagen) 2 µl 
MgCl2 (25 mM) (Qiagen) 1.25 µl 
Q-solution (Qiagen) 4 µl 
dNTPs (1 mM) 1 µl 
Sense Primer (2 µM) 1 µl 
Antisense Primer (2 µM) 1 µl 
Taq DNA Polymerase 
(5 U/µl) (Qiagen) 
0.1 µl 
Aqua bidest. 8.65 µl 
Template 1 µl 
Total volume 20 µl 
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The PCR conditions used are listed below: 
 
Table 3.4:  Reaction conditions RIP2-hGIPRdn PCR 
 
 RIP2-hGIPRdn  
Denaturation 95°C  15 min  
Denaturation 94°C   1 min  
Annealing 62°C   1 min 35 x 
Elongation 72°C   1 min  
Final elongation 72°C 10 min  
 
 
Table 3.5:  Reaction conditions β-actin PCR 
 
 β-actin  
Denaturation 94°C   4 min  
Denaturation 94°C   1 min  
Annealing 58°C   1 min 35 x 
Elongation 72°C   1 min  
Final elongation 72°C 10 min  
 
Finally, the thermocycler cooled down to 4°C. For short-term storage samples were 
kept in the refrigerator and for long-term storage at –20°C. As positive control, 
plasmid DNA including the RIP2-GIPRdn construct or genomic DNA of a previously 
genotyped transgenic pig was used. Aqua bidest. served as negative control (non-
template control). 
 
3.3.4.1.3 Agarose gel electrophoresis 
The agarose gel electrophoresis allows separation of DNA strands according to their 
size. For separation of the DNA TAE-agarose gels were used. The gel solution was 
boiled in the microwave and thereafter ethidiumbromide, a dye which intercalates 
between the bases of nucleic acids whereby DNA can be visualized under UV-light, 
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was added at a final concentration of 0.5 µg/ml. Samples as well as a DNA molecular 
weight standard were mixed with 6x loading dye so that the progression of the gel 
electrophoresis could be estimated and pipetted into the gel slots before gel 
electrophoresis was started. All agarose gels were documented under UV-light 
(254 nm) using a gel documentation system (Intas). 
 
3.3.4.2 Southern Blot 
3.3.4.2.1  Isolation of genomic DNA from EDTA blood 
Genomic DNA was isolated from 5 ml EDTA blood using the Blood & Cell Culture 
DNA Midi Kit® (Qiagen) according to the manufacturer’s instructions. 
 
3.3.4.2.2  Restriction digest 
Genomic DNA (8 µg) was incubated overnight along with 30 U of the restriction 
enzyme ApaI, its appropriate buffer as well as 0.1 M spermidine in a total volume of 
30 µl at 37°C. The next day another 10 U of the restriction enzyme were added per 
sample followed by an incubation step of one hour. Subsequently, 6x loading dye 
was added to all samples before they were used for agarose gel electrophoresis. 
 
3.3.4.2.3  Gelelectorphoresis and transfer of genomic DNA 
DNA fragments were separated using a 0.9% TAE agarose gel and the 1 kb ladder 
as DNA molecular weight standard. Gelelectrophoresis was discontinued as soon as 
the samples, visualized by the bromophenol blue containing 6 x loading dye, had 
been reached the end of the gel and documented under UV-light using a gel 
documentation system. After that the gel was pivoted in 0.25 M hydrochloric acid for 
about 20 minutes depending on the color shift of the bromophenol blue bands to 
yellow. Then the gel was washed with aqua bidest. and incubated in denaturation 
solution until the color of the bands turned back to blue (around 45 minutes). 
Subsequently, the previously digested and separated genomic DNA was transferred 
to a positive loaded Nylon membrane (Nylon-N+, GE Healthcare) by capillary 
transfer. The assembly of a Southern blot is shown in Figure 3.2. After a transfer time 
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of 18-24 hours, the membrane was soaked in neutralization solution for five minutes 
and then air-dried. Cross linking of the transferred DNA with the membrane was 
accomplished under UV light (120 J/cm2) before the membrane could be stored at 
room temperature until further processing. 
glass top
glass top
Agarose gel
Hybond-N+ Nylon membrane
Whatman-paper
Absorbant paper
Weight (~ 800 g)
 
Figure 3.2:  Schematic description of the assembly of a Southern blot. 
 
3.3.4.2.4  Probe establishment 
A 720-bp probe was created using the primers RIP2-sense and RIP2-antisense (see 
also chapter 3.3.4.1.2). Plasmid DNA containing the RIP2-hGIPRdn construct in a 
concentration of 7 ng/µl served as template. 
 
Table 3.6:  Reaction batch probe Southern blot PCR 
 
 Probe Southern blot 
10 x Herculase buffer 10 µl 
dNTPs (10 mM) 2 µl 
Sense primer (100 µM) 0.5 µl 
Antisense primer (100 µM) 0.5 µl 
Aqua bidest. 83.5 µl 
Herculase Taq Polymerase 0.5 µl 
Template 3 µl 
Total volume 100 µl 
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Table 3.7:  PCR conditions probe Southern blot PCR 
 
 Probe Southern blot  
Denaturation 94°C 4 min  
Denaturation 94°C 1 min  
Annealing 62°C 1 min 34 x 
Elongation 72°C 3.03 min  
Final elongation 72°C 10 min  
 
The PCR product was applied to a 1% TAE-agarose gel after addition of 20 µl 6x 
loading dye. Then, the designated band was excised using a scalpel blade and DNA 
was extracted from the gel using the Jetquick Gel Extraction Spin Kit according to the 
manufacturer’s instructions. Then 2 µl of each extracted DNA sample as well as of 
the molecular weight standard Lambda/ HindIII + EcoRI were loaded on a 1% TAE 
agarose gel. DNA concentration was estimated by comparison of the band intensity 
of the DNA samples with the different band intensities of the known DNA 
concentration of the molecular weight standard Lambda/ HindIII + EcoRI. 
 
3.3.4.2.5 Radioactive labeling of the probe 
50-70 ng of the probe were radioactively labeled with 50 µCi α-[32P]-dCTP (GE 
Healthcare) using the Rediprime II Random Prime Labeling System® according to the 
manufacturer’s instructions. Random priming is a method to label DNA. Here 
previously denatured single strand DNA is hybridized with oligonucleotides of 
accidental sequence. The labeling is carried out by the integration of radioactive 
nucleotides. The Klenow fragment of Polymerase I is used as Polymerase. All not 
incorporated nucleotides are removed with a MicroSpinTM S-300 HR column. Nuclear 
radiation per minute (cpm: counts per minute) is measured using a scintillation 
counter. For this 5 µl of a 1:100 dilution of the labeled probe were utilized. The cpm 
value per µl of the labeled probe was calculated according to the following formula 
where Cerenkov is a correction factor for the calculation without scintillation liquid: 
cpm/µl = cpm * 20 (dilution) * 1.55 (Cerenkov) 
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3.3.4.2.6 Hybridization, washing and signal detection 
Prior to hybridization the Nylon membrane was prehybridized in Rapid-Hyb buffer®  
for two hours at 65°C in a hybridization oven. The hybridization was carried out 
overnight also at 65°C. For this, the labeled probe was utilized in a concentration of 
2 x 106 cpm per µl Rapid-Hyb buffer®. The adequate amount of probe was denatured 
for five minutes at 95°C, chilled on ice and added to the prehybridization solution. 
The following day three washing steps were performed to remove nonspecific bound 
radioactivity: 1 x washing solution I for 20 minutes (RT); 2 x washing solution II for 20 
minutes (65°C). Blots were exposed in a Phosphor-Imager cassette and visualized 
with a Phosphor-Imager (Storm 860). 
 
3.3.4.2.7 Stripping of the membrane 
Before application of another probe the previously used probe was removed by 
stripping of the membrane. For this, the moist Nylon membrane was transferred to a 
hybridization glass tube filled with boiling hot 0.1% SDS solution. After ten minutes 
the solution was renewed and the glass tube rolled until it had reached room 
temperature. Then the membrane was either immediately reused or air-dried. 
 
3.3.5 Expression analysis by Reverse Transcriptase-PCR (RT-PCR) 
Expression of the GIPRdn transgene on RNA level was investigated in porcine islets 
of Langerhans. 
3.3.5.1 Isolation of total RNA from porcine islets of Langerhans 
Total RNA was extracted using TRIzol® Reagent, a monophasic solution of phenol 
and guanidinium isothiocyanate, according to the manufacturer’s instructions. 
Therefore, porcine islets of Langerhans (transgenic animals: 4,000-5,000 IEQ; wild-
type animals: 10,000 IEQ) in culture media were centrifuged at 350 rpm (Rotanta 96; 
Hettich) for three minutes, the supernatant was discarded and the pellet resuspended 
in 1 ml TRIzol® Reagent. A former washing step with PBS was neglected because 
this could have led to an elevated mRNA degradation. Linear acrylamide was used 
as coprecipitate (5 µg per sample) because of the small number of islet equivalents 
 51
Animals, Materials and Methods 
available per sample, especially in the transgenic animals. Quantification of total 
RNA was conducted using a NanoDrop-1000 spectrophotometer. 
 
3.3.5.2 DNaseI digest and reverse transcription 
In order to eliminate a possible DNA contamination of the RNA sample, about 1.4 µg 
of total RNA were incubated with 20 U of DNaseI in a total volume of 20 µl at 37°C 
for 30 minutes. The enzyme was inactivated at 75°C for ten minutes. 
 
 Total RNA  x µl (= 1.4 µg) 
 DNaseI reaction buffer  2 µl 
 DNaseI, RNase-free  2 µl 
 Deionized water  ad 20 µl 
 
The RNA was quantified again using a NanoDrop-1000 spectrophotometer and 400 
ng of total RNA were used for reverse transcription with the SuperScriptTM II Reverse 
Transcriptase (Invitrogen) in a total volume of 20 µl. 
 
 Random Primers (3 µg/µl) 1 µl 
 dNTPs (10 mM) 1 µl 
 RNA, DNaseI digested (400 ng) x µl 
 Deionized water ad 12 µl 
 Æ Incubation 5 min, 65°C 
 Æ chill on ice 
 
 5 x first strand buffer 3 µl 
 DTT (100 mM) 2 µl 
 RNase OUT 1 µl 
 Æ Incubation 2 min, 25°C 
 
 5 x first strand buffer 1 µl 
 SuperScriptTMII RT (200 U/µl) 1 µl 
 Æ Incubation 10 min, 25°C 
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 Æ Incubation 50 min, 42°C 
 Æ Incubation 15 min, 70°C 
 
Following the inactivation of the enzyme at 70°C, the cDNA was chilled on ice, 
centrifuged and stored at -20°C until further processing. The integrity of the DNaseI 
digest was tested by a minus RT reaction of all samples. Both, RNA of all three wild-
type animals and RNA of the transgenic pigs were pooled in two separate reaction 
tubes and reverse transcription was performed according to the previously described 
protocol. Instead of SuperscriptTMII Reverse Transcriptase, 1 µl of deionized water 
was added. 
 
3.3.5.3 RT-PCR 
For determination of the transgene expression, the following transgene-specific 
primers were applied: 
GIPRdn (sense):  5’-TTTTTATCCGCATTCTTACACGG-3’ 
GIPRdn (antisense):  5’-ATCTTCCTCAGCTCCTTCCAGG-3’ 
As template 2 µl of the cDNA were set in the following PCR-reaction: 
 
Table 3.8:  Reaction batch GIPRdn RT-PCR 
 
10 x buffer (Qiagen) 2 µl 
MgCl2 (25 mM) (Qiagen) 1.25 µl 
dNTPs (1 mM) 2 µl 
Sense Primer (2 µM) 2 µl 
Antisense Primer (2 µM) 2 µl 
HotStar Taq DNA Polymerase 
(5 U/µl) (Qiagen) 
0.1 µl 
Aqua bidest. 8.65 µl 
Template (cDNA) 2 µl 
Total volume 20 µl 
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Table 3.9:  PCR conditions GIPRdn RT-PCR 
 
Denaturation 95°C 15 min  
Denaturation 94°C   1 min  
Annealing 62°C   1 min 35 x 
Elongation 72°C   1 min  
Final elongation 72°C 10 min  
 
The β-actin PCR reaction batch and conditions were used as described in  
Table 3.3 and Table 3.5. Gel electrophoresis for visualization of the PCR result was 
carried out as described in 3.3.4.1.3. 
 
3.3.6 Analysis of glucose metabolism 
The glucose metabolism was analyzed through baseline parameters like blood/serum 
glucose and serum fructosamine determination as well as through different 
provocation assays, i.e., oral glucose tolerance test (OGTT), intravenous glucose 
tolerance test (IVGTT), GIP or Exendin-4 stimulation test and glucagon stimulation 
test (GST). 
 
3.3.6.1 Blood glucose and serum fructosamine levels 
For determination of blood glucose levels in pigs, a small drop of blood was collected 
from the ear vein with a lancet. This method causes minimal stress for the animals. 
Blood glucose was immediately determined using a plasma calibrated Precision® 
XceedTM Glucometer (Abbott) with XtraTM Plus control stripes (Abbott). 
Blood samples for determination of serum fructosamine levels were taken from the 
jugular vein in restrained animals as this parameter is not influenced by stress and a 
larger volume of blood is needed. After an incubation period of 20 minutes at room 
temperature, serum was separated by centrifugation (20 minutes, 10,000xg) and 
stored at -80°C until assayed. Fructosamine levels were determined in the Medical 
Small Animal Clinic (LMU, Munich), using a Hitachi 911 autoanalyzer (Roche) and 
adapted reagents (Roche). Both parameters were analyzed once in unfasted pigs 
 54
Animals, Materials and Methods 
before weaning and several times in fasted pigs (18-hour fasting period) after 
weaning. The number of animals investigated included five transgenic animals as 
well as five non-transgenic littermate controls. 
 
3.3.6.2 Preliminary work for the provocation tests 
During all study procedures, animals were housed in single pens under controlled 
conditions. At the beginning of all provocation tests, animals were well trained and 
accustomed to the person conducting the analyses in order to generate an 
environment with as minimal stress as possible. Additionally, pigs were trained to eat 
food supplemented with glucose so they would eat glucose within the preset time-
frame during an OGTT. 
 
3.3.6.3 Non-surgical implantation of a central venous catheter 
One central venous catheter was inserted non-surgically in 5-month-old pigs used for 
an oral glucose tolerance test (OGTT). The procedure was performed by a modified 
method of Matte (Matte 1999) under general anesthesia, using a combination of 2 ml 
per 10 kg BW ketamine hydrochloride (Ursotamin®, Serumwerk Bernburg) and 0.5 ml 
per 10 kg BW xylazine (Xylazin 2%, WDT) injected intravenously. Pigs were 
restrained in dorsal recumbency with the head downwards at an angle of 
approximately 30° with the table. One jugular grove was shaved, washed carefully 
with Vet-Sept® solution (10%) and disinfected with alcohol (70%). A central venous 
catheter (Cavafix®Certo®, B. Braun Melsungen) was aseptically placed into the 
external jugular vein according to the manufacturer’s instructions. External fixation 
was carried out by a single suture of adhesive tape, placed around the catheter, to 
the skin. Further, the catheter was covered with sterile gauze and adhesive tape up 
to the withers level where it was coiled in a pouch to provide easy access. An 
antibiotic (Cobactan® 2.5%, Intervet) was administered once (0.5 ml/10 kg BW) after 
catheter placement. The catheter was flushed with 250 IU heparin/ml 0.9% isotonic 
NaCl solution (Heparin-Natrium, B. Braun, 0.9% NaCl, B. Braun) once daily. 
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Figure 3.3:  Non-surgical placement of a central venous catheter 
 (A) puncture of the external jugular vein with a puncture cannula under aspiration; after 
successful puncture removal of the steel cannula; (B) insertion of the catheter through the 
guiding plastic cannula; (C) removal of the guiding plastic cannula by splitting the cannula in 
two parts; (D) Cavafix® Certo® central venous catheter placed in the external jugular vein; 
part of the catheter outside of the vein surrounded by a plastic protection cover. 
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3.3.6.4 Surgical placement of a central venous catheter 
For accomplishment of the intravenous glucose tolerance test as well as the 
glucagon stimulation test and GIP/Exendin-4 stimulation test, two central venous 
catheters (Cavafix® Certo®, B. Braun) were surgically inserted into the external 
jugular vein under general anesthesia, using a combination of 2 ml per 10 kg BW 
ketamine hydrochloride (Ursotamin®, Serumwerk Bernburg) and 0.5 ml per 10 kg BW 
xylazine (Xylazin 2%, WDT) injected intravenously. After aseptic preparation of the 
surgical field a skin incision, five centimeters in length, was made followed by the 
exposure of the external jugular vein. One holding suture was placed proximally and 
distally to the intended site of cannulation, a venotomy was made and the catheters 
were inserted 15 cm into the vein. A ligature was placed proximally and distally of the 
venotomy site and the incision was closed in two layers. External fixation of the 
catheters was performed as described in 3.3.6.3. Peri- and postsurgical analgesia 
were maintained by intramuscular injection of 1 ml/10 kg BW Metamizol (Vetalgin®, 
Intervet). Postsurgical infection of the surgical site was prevented by intramuscular 
injection of 0.5 ml/kg BW Cefquinom (Cobactan® 2.5%, Intervet) once daily for three 
days. The catheters were flushed with 250 IU heparin/ml 0.9% isotonic NaCl solution 
(Heparin-Natrium, B. Braun, 0.9% NaCl, B. Braun) once daily. 
At the beginning of the study period, all animals had fully recovered from the surgical 
procedure as was indicated by the presence of normal behavior and food intake. 
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Figure 3.4:  Surgical placement of a central venous catheter 
(A) Exposed external jugular vein; white arrows indicate the outline of the vein; (B) external 
jugular vein advanced by a retention stitch; removal of the adjacent connective tissue; (C) 
vein after venotomy; (D) two Cavafix® Certo® catheters located in the external jugular vein. 
 
3.3.6.5 Oral glucose tolerance test 
The OGTT was performed in 5-month-old non restrained freely moving animals. After 
an 18-h overnight fast, animals were fed 2 g/kg BW glucose (Larsen et al. 2003) 
mixed with 100 g of commercial pig fodder. The meal was eaten from a bowl under 
supervision. Blood samples were obtained from the jugular vein catheter at -15, -5, 0, 
15, 30, 45, 60, 90, 120, 150 and 180 minutes relative to the glucose load. Blood 
glucose was immediately determined using a Precision® XceedTM Glucometer 
(Abbott). For insulin measurement, blood was collected in serum monovettes and 
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immediately put on ice. Separation of serum by centrifugation (20 minutes, 
10,000 xg) was followed by storage at -80°C until samples were assayed. Serum 
insulin levels were determined using a porcine insulin radioimmunoassay kit 
(Millipore) as described in 3.3.6.10. 
 
3.3.6.6 Intravenous glucose tolerance test 
The IVGTT was performed in pigs 8 weeks, 7 month (28-36 weeks) and 10 month 
(45 weeks ± 2 weeks) of age. After an 18-h overnight fast, a bolus injection of 
concentrated 50% glucose solution (0.5 g glucose/kg BW) was administered 
(Kobayashi et al. 2004) through the central venous catheter number one. 
Subsequently, catheter one was flushed with 40 ml of 0.9% isotonic NaCl solution. 
Blood was collected through catheter number two at -15, -5, 0, 1, 3, 5, 10, 20, 30, 40, 
50, 60, 120 and 180 minutes relative to the glucose load in 7- and 10-month-old pigs 
and at -15, 0, 1, 5, 10, 20, 30, 40, 60 minutes relative to the glucose load in 8-week-
old animals. For serum glucose and insulin measurements, blood was collected in 
serum monovettes and immediately put on ice. Separation of serum by centrifugation 
(20 minutes, 10,000 xg) was followed by storage at -80°C until samples were 
assayed. Serum glucose levels were measured using an AU 400 autoanalyzer 
(Olympus). Serum insulin levels were determined by RIA as described in 3.3.6.10. 
 
3.3.6.7 GIP stimulation test 
The GIP stimulation test was performed in 8-week- and 7-month-old (28-36 weeks) 
non-restrained freely moving animals. Following an 18-hour fasting period, 0.5 g/kg 
BW of 50% glucose solution (Kobayashi et al. 2004) were administered as a bolus 
through a central venous catheter. Three minutes later, 20 pmol/kg BW of synthetic 
porcine GIP (Bachem) were mixed with 5% porcine serum in 5 ml of 0.9% NaCl and 
immediately administered intravenously. Blood samples were collected at -10, 0, 1, 6, 
9, 11, 13, 18, 23, 28, 33, 48 and 60 minutes relative to the glucose load in 7-month-
old pigs and at -10, 0, 1, 5, 10, 13, 18, 20, 23, 30, 40 and 60 minutes relative to the 
glucose load in 8-week-old pigs. Sample handling as well as serum glucose and 
serum insulin determination was performed as described in 3.3.6.6. The day before 
the GIP stimulation test, an IVGTT using 0.5 g/kg BW of 50% glucose solution was 
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performed and serum glucose and insulin levels were determined at time points as 
indicated in 3.3.6.6. 
 
3.3.6.8 Exendin-4 stimulation test 
The Exendin-4 stimulation test was performed in 8-week- and 7-month-old (28-36 
weeks) non-restrained freely moving animals. Following an 18-hour fasting period, 
0.5 g/kg BW of 50% glucose solution (Kobayashi et al. 2004) were administered as a 
bolus through the central venous catheter. Three minutes later 10 pmol/kg BW of 
synthetic Exendin-4 (Bachem) were mixed with 5% porcine serum in 5 ml of 0.9% 
NaCl and administered immediately intravenously. Blood samples were collected at  
-10, 0, 1, 6, 9, 11, 13, 18, 23, 28, 33, 48 and 60 minutes relative to the glucose load 
in 7-month-old pigs and at -10, 0, 1, 5, 10, 13, 18, 20, 23, 30, 40 and 60 minutes 
relative to the glucose load in 8-week-old pigs. Serum glucose and serum insulin 
levels were determined as described in 3.3.6.6. Two days before the Exendin-4 
stimulation test, an IVGTT using 0.5 g/kg BW of 50% glucose solution was performed 
and serum glucose and insulin levels were determined at time points as indicated in 
3.3.6.6. 
 
3.3.6.9 Glucagon stimulation test (GST) 
The glucagon stimulation test evaluates insulin secretion in response to maximal 
stimulation by glucagon. In human medicine this test is routinely used to estimate the 
remaining β-cell reserve and therefore the need of exogenous insulin in diabetic 
patients. In the present study, GST was used to estimate the insulin secretory 
capacity of GIPRdn transgenic pigs compared to non-transgenic control animals. The 
test was performed in 45-week-old pigs on average. Animals were fasted overnight 
(18 hours) before administration of 1 mg of Glucagon (GlucaGen®, Novo Nordisk) 
through the central venous catheter number one. Immediately afterwards, the 
catheter was flushed with 20 ml of 0.9% isotonic NaCl solution. Blood samples were 
obtained at -10, -5, 0, 2, 4, 6, 8, 10, 15, 20, 25, 30, 35 and 40 minutes relative to the 
glucose load. Sample handling as well as serum glucose and serum insulin 
determination was performed as described in 3.3.6.6. 
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3.3.6.10 Determination of serum insulin concentrations by radioimmunoassay 
 (RIA) 
To analyze serum insulin levels over the course of an OGTT, GIP/Exendin-4 
stimulation test, IVGTT and GST, a porcine insulin RIA kit (Millipore, Billerica), which 
is a competitive radioimmunoassay, was used according to the manufacturer’s 
instructions. In this RIA, a fixed concentration of labeled tracer antigen (125I labeled 
insulin) was incubated with a constant dilution of anti-porcine insulin antiserum such 
that the concentration of antigen binding sites on the antibody was limited. If 
unlabeled insulin in the form of a serum sample was added to this system, there was 
competition between labeled tracer and unlabeled insulin for the limited and constant 
number of binding sites on the antibody. Thus, the amount of tracer bound to 
antibody decreased as the concentration of unlabeled antigen increased. This was 
measured after separating antibody-bound from free tracer and counting the 
antibody-bound fraction in a γ-counter. A calibration or standard curve was set up 
with increasing concentrations of standard unlabeled insulin and from this curve the 
amount of insulin in unknown samples was calculated. All samples were measured in 
duplicate. Only duplicates with a coefficient of variance (CV) less than 10% were 
accepted. 
 
3.3.7 Isolation of porcine islets of Langerhans 
3.3.7.1 Islet isolation procedure 
Pancreatic islets were isolated from GIPRdn transgenic pigs (n=3; two females, one 
male; 220 kg) and littermate control pigs (n=3; three females; 220 kg). Pancreata 
were harvested from slaughtered pigs under semi-sterile conditions on four 
consecutive days. The organs were crudely dissected from fat, blood vessels and 
connective tissue and explanted in toto. Total warm ischemia time was five minutes. 
After canulating the major pancreatic duct with a Cavafix® Certo 18G catheter (B. 
Braun, Melsungen, Germany) the organs were transferred to ice-cold HBSS solution 
(pH 7.2; Cell Concepts, Umkirch, Germany), and shipped on ice to the laboratory 
where a final dissection of fat, blood vessels and connective tissue was performed. 
For separation of the left pancreatic lobe which was used for islet isolation, the small 
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incision at the basis of the lobe right before it fades to the rest of the organ was 
marked on one side of the lobe. To recover the same point on the opposite side of 
the lobe base, the distance between the previously described incision and the tip of 
the lobe was measured using a compass and the same distance was marked out on 
the other side of the lobe. The left pancreatic lobe was then separated using a sharp 
blade following an imaginary line connecting the two previously marked points. 
Subsequently, both parts were weighed and the rest of the pancreas lacking the left 
lobe was prefixed in 10% neutral buffered formalin for approximately six hours for 
subsequent stereological analyses (see also 3.3.8). The left lobe of the pancreas was 
then distended, via the catheter, with 200 ml of 20°C warm University of Wisconsin 
(UW) solution, containing 4 PZ units NB8 collagenase (Nordmark, Uetersen, 
Germany) per gram of organ and 0.7 DMC units neutral protease (Nordmark). The 
pancreata were digested using a modification of the half-automated digestion-
filtration method previously described by Ricordi et al. and Heiser et al. (Ricordi et al. 
1990; Heiser et al. 1994). In brief, the organ was cut into five pieces that were placed 
into the digestion chamber containing a stainless steel mesh with 500 µm pore size 
and four stainless steel marbles. The system was filled with UW solution that passed 
a heating circuit to maintain a stable temperature of 32-37°C during the digestion 
process. Samples were taken every minute from minute 15 onwards and stained with 
dithizone (Sigma, Taufkirchen, Germany) to monitor the degree of tissue digestion 
(see also 3.3.7.4.1) (Latif et al. 1988). The isolation process was stopped after 20-25 
minutes by flushing the system with ice-cold HBSS that contained 25 mM KH2PO4 
buffer and 13% heat-inactivated FCS (FCS; Cell Concepts) when the first islet, free 
of surrounding exocrine tissue, was detected in the biopsy. The digest was collected 
in plastic tubes, washed twice at 250 xg and stored for 1 hour on ice in 10% FCS and 
50 mM nicotinamide-containing UW solution. The non-digested tissue from the 
digestion chamber was weighed and not considered for calculation of the isolation 
result. 
Purification of the isolated islets from the digest was performed with the 
discontinuous OptiPrep™ density gradient (Progen, Heidelberg, Germany) in the 
COBE 2991 cell processor (short: COBE; COBE Inc., Colorado, USA) (Krickhahn et 
al. 2001; van der Burg & Graham 2003). The digest was washed at 200 xg, 
resuspended in 200 ml UW solution, mixed with 120 ml working solution (two times 
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concentrated UW solution, and the same amount of OptiPrep™ at a density of 1.206 
g/ml) and loaded into the COBE. During centrifugation at 1,000 rpm, 96 ml of low-
density solution (a mixture of working solution and UW solution with a density of 
1.206 g/ml) and 120 ml UW solution were loaded into the COBE. After further 
centrifugation for five minutes at 1,000 rpm the COBE was unloaded. The first 50 ml 
were discarded; the remaining suspension was collected in fractions of 30 ml on ice. 
Purified islets were washed with UW solution, were resuspended and transferred to 
two 30-ml culture flasks (Greiner, Nürtingen, Germany) and were cultured overnight 
in 30 ml HAM’S F12 culture medium (Cell Concepts; supplemented with 10% FCS, 
1% amphotericine B, 1% L-glutamine, 1% ampicilline/gentamycine and 50 mM 
nicotinamide) at 24°C and 5% CO2 in air. 
 
3.3.7.2 Determination of islet numbers 
After enzymatic digestion and purification, islet numbers were determined. 100-µl 
islet samples (triplicates) were stained with dithizone (DTZ) for differentiation of islets 
of Langerhans and exocrine tissue and counted under an Axiovert 25 microscope 
(Zeiss, Oberkochen, Germany) with a calibrated grid in the eyepiece. Counted islets 
were grouped into size categories and converted into islet equivalents (IEQ), i.e., 
islets with an average diameter of 150 µm. The isolation result was then indicated as 
total IEQ and IEQ per gram of digested organ (Krickhahn et al. 2001). 
 
3.3.7.3 Determination of islet purity and islet vitality 
To determine the purity of the islets, 50-µl samples (triplicates) were taken from the 
culture flasks, transferred to glass slides and mixed with 50 µl DTZ solution each. 
The percentage of contaminating exocrine debris (unstained) was estimated and 
compared to the red-stained islets. 
Vitality of the islets was examined at a wavelength of 488 nm underneath a BX50 
fluorescence microscope (Olympus, Hamburg, Germany) and fluorescence was 
visualized using a 530 ± 20 nm bandpass filter. 1.5 µl of freshly prepared fluorescein 
diacetate solution (FDA, Sigma-Aldrich; 1 mg in 1 ml acetone) and 10 µl propidium 
iodide (PI, Sigma-Aldrich; 5 mg in 10 ml PBS) were added to 20-30 islets in 1 ml 
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HAM’S F12 culture medium. The islet suspension was then screened under the 
microscope and vitality was estimated by two independent individuals. 
FDA is a non-polar ester which passes through plasma membranes and is 
hydrolyzed by intracellular esterases to produce free fluorescein. The polar 
fluorescein is unable to pass through the intact cell membrane of living cells and thus 
accumulates and produces a green cytoplasmatic fluorescence under appropriate 
excitation conditions. PI is excluded from intact cells and permeates only through the 
membranes of dead or dying cells where it binds to nucleic acids and produces a 
bright red nuclear fluorescence. 
 
 
Figure 3.5:  Determination of islet vitality by FDA/PI staining 
Native (A) and FDA/PI stained (B) porcine islet of Langerhans after 20 days of in vitro 
culture; all green stained areas are indicative for viable islet cells while red stained areas 
show dead islet cells; magnification 40 x; scale bar 200 µm. 
 
3.3.7.4 Production of frozen sections 
While detectable antigens are much better conserved in frozen sections compared to 
paraffin sections, the conservation of morphological details is worse in frozen section. 
Small sections (0.5 cm in diameter) of the left pancreatic lobe free from fat, 
connective tissue, blood vessels and lymph nodes were transferred to cryotubes 
(Brand GmbH; Wertheim), filled with a special cryomedium (Tissue Tek, Sakura 
Finetek Europe B. V.; Zöterwoude, Holland) and immediately frozen in liquid nitrogen 
at -196°C to prevent the development of ice crystals. Blocks were stored at  
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-80°C until further processing. At least one hour prior to the production of frozen 
sections, tissue blocks were stored in the cryostat (Frigocut-N-2800, Reichert Jung; 
Bensheim) at -20°C. Subsequently, ~5 µm thick sections were cut in the cryostat 
using a C-blade (Leica; Nussloch) at -20°C and mounted on silanized glass slides 
(HistobondTM, Marienfeld, Lauda-Königshofen). Sections were then dried for two 
hours at room temperature and stored at -20°C until further assayed. 
 
3.3.7.4.1 Dithizone staining 
Dithizone (diphenylthiocarbazone) is a zinc-specific stain used for the differentiation 
of islets of Langerhans and exocrine tissue components. While zinc containing β-
cells are stained red, exocrine acinous cells remain unstained. Therefore 10 mg 
Dithizone (Sigma-Aldrich) were dissolved in 1 ml dimethyl sulfoxyd (Sigma Aldrich). 
Nine ml HBSS were added and the solution was filtered using a 0.2 µm filter. 100 µl 
of the Dithizone solution were added per frozen section and the immediate staining of 
the section was analyzed under a light microscope. 
 
3.3.7.4.2 Immunohistochemistry for insulin 
At first frozen sections were fixed in acetone for 10 minutes at 4°C and then dried for 
15 minutes at RT. Subsequently, endogenous peroxidase was blocked for 15 
minutes at RT using a methanol-hydrogen-peroxide mixture (200 ml methanol + 3 ml 
H2O2 30%). After that sections were washed three times with PBS (pH 7.4), followed 
by saturation of the tissue antigens with a protein block (normal goat serum, 
BioGenex, San Ramon, USA) in order to prevent nonspecific antibody binding 
(incubation ten minutes at RT). Incubation of the sections with the primary polyclonal 
guinea pig-anti-porcine insulin antibody (dilution 1:75) (Dako Cytomation, Hamburg) 
was carried out overnight in the refrigerator. A background reducing medium was 
used (Dako Cytomation) to dilute the antibody. Then sections were washed again 
three times with PBS, followed by an incubation step with a peroxidase conjugated 
goat-anti-guinea pig secondary antibody (dilution 1:1000); (Rockland; Gilbertsville, 
USA) in addition to 10% porcine serum (Serotec, Duesseldorf) for 30 minutes at RT. 
Afterwards, sections were washed three times with PBS. Immunoreactivity was 
visualized using the Peroxid-Block-Kit (BioGenex, Hamburg). For this, two drops of 
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3,3´ diaminobenzidine tetrahydrochloride (DAB) as well as one drop of H2O2 were 
added to the prepared substrate buffer according to the manufacturer’s instructions, 
mixed and incubated for approximately three minutes under microscopic control until 
sufficient dye intensity was reached. Slides were washed with deionized water, 
counterstained with Mayer’s hemalaun solution and washed again before they were 
dehydrated in an ascending alcohol series, cleared in xylene (Merck, Darmstadt) and 
mounted under coverslips using Pertex (Medite GmbH, Burgdorf). 
 
All islet isolation procedures as well as preparation and staining of frozen sections 
were carried out in collaboration with Prof. K. Ulrichs, Dr. I. Chodnevskaja and B. 
Schneiker (Experimental Transplantation Immunology, Surgical Clinic I, University 
Hospital of Würzburg, Germany). 
 
3.3.8 Quantitative stereological analyses 
3.3.8.1 Pancreas preparation and quantitative stereological analyses 
Following prefixation to allow manipulation of the organ without damaging the tissue, 
the pancreas (without left lobe) was cut into 1 cm thick slices, slices were tilted to 
their left side and covered by a 1 cm2 point-counting grid which was used for area-
weighted subsampling of pancreas tissue for quantitative stereological analyses. As 
pancreas slices were of the same thickness this procedure represents volume-
weighted subsampling. The total number of points hitting pancreas tissue was 
determined. One tenth of the total number of points hitting pancreas tissue yielded 
the total sample number. For determination of the sites of sample collection, a 
random number (X) between one and the quotient of total hitting points and total 
sample number (Y) was determined. Pieces with a volume of 0.5 cm3 were taken at 
the sites X+Y; X+2*Y; X+3*Y … Selected samples were placed in an embedding 
cassette with the right cut surface facing downwards, fixed in 10% neutral buffered 
formalin at room temperature overnight, routinely processed and embedded in 
paraffin. From half of the paraffin embedded samples a series of sections of 
approximately 4 µm thickness was cut with a HM 315 microtome (Microm). One 
section from each series was mounted on a glass slide for hematoxylin and eosin 
(H&E) staining and the following section was mounted on a 3-aminopropyltriethoxy-
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silane-treated glass slide for immunohistochemistry. All H&E stained sections as well 
as a sheet of millimeter paper for calibration purposes were photocopied at a final 
magnification of 400% on a commercial photocopier showing the complete cut 
surface of all pancreas slices. Morphometric evaluation was carried out on a 
Videoplan® image analysis system (Zeiss-Kontron, Eching, Germany) attached to a 
microscope by a color video camera. The cross-sectional area of the pancreas was 
determined planimetrically by circling the cut surfaces on the photocopies. 
Planimetric measurements of islet profiles were performed on H&E stained sections 
while β-cell areas were determined on immunohistochemically stained sections (see 
3.3.8.3) by circling their outlines with a cursor on a digitizing tablet of the image 
analysis system. Images were displayed on a color monitor at an 850x final 
magnification. The volume of the pancreas (V(Pan)) before embedding was calculated 
by the quotient of the pancreas weight and the specific weight of the pig pancreas 
(1.07 g/cm3). The specific weight was determined by the submersion method 
(Scherle 1970). The volume density of the islets in the pancreas (Vv(Islet/Pan)) was 
calculated by dividing the total islet area (A(Islet)) by the total pancreas area (A(Pan)). 
The total volume of islets in the pancreas (V(Islet, Pan)) was determined as the product 
of Vv(Islet/Pan) and V(Pan). Accordingly, the volume density of β-cells in the pancreas 
(Vv(β-cell/Pan)) was obtained as the quotient of the total area of β-cells (A(β-cells)) and 
A(Pan). Here, total area of β-cells included total area of β-cells in the islets and total 
area of isolated β-cells in the pancreas. Further, the total volume of β-cells in the 
pancreas was determined as the product of Vv(β-cell/Pan) and V(Pan). Division of A(β-cell) 
by A(Islet) yielded the volume density of the β-cells in the islets (Vv(β-cell/Islet)) and the 
product of Vv(β-cell/Islet) and V(Islet, Pan) resulted in the total volume of β-cells in the islets 
(V(β-cell, Islet)). 
Isolated β-cells (insulin positive single cells and small clusters of insulin positive cells 
not belonging to established islets) were quantified separately. The volume density of 
isolated β-cells in the pancreas was obtained by division of the total profile areas of 
isolated β-cells by A(Pan). The total volume of isolated β-cells was determined as the 
product of their volume density in the pancreas and the total volume of the pancreas. 
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Figure 3.6:  Pancreas preparation for islet isolation and quantitative stereological 
analyses 
White arrows indicate the separation site of the left pancreatic lobe from the rest of the organ 
using the left pancreatic lobe for islet isolation and the remnant organ for quantitative 
stereological analyses. 
 
3.3.8.2 Hemalaun & Eosin staining 
After incubation overnight at 37°C in an incubator, sections were deparaffinized in 
xylene for 15 minutes, rehydrated in a descending alcohol series and washed in 
distilled water. Subsequently nuclear staining was carried out by incubation of the 
slides in Meyer’s Hemalaun solution for four minutes. Then tissue sections were 
washed with tap water for five minutes and dipped four to five times in eosin solution. 
Sections were dehydrated in an ascending alcohol series, cleared in xylene and 
mounted under coverslips using Eukitt® (Electron Microscopy Sciences). 
 
3.3.8.3 Immunohistochemistry for insulin 
The indirect immunoperoxidase technique was applied to localize insulin containing 
cells. Sections were deparaffinized in xylene, rehydrated in a descending alcohol 
series and washed in distilled water. Endogenous peroxidase activity was blocked 
using 1% hydrogen peroxide in TBS buffer (pH 7.4). After that sections were washed 
in TBS (pH 7.4) for ten minutes and pre-incubated with normal rabbit serum (MP 
Biomedicals) for 30 minutes to reduce non-specific binding. Subsequently, slides 
were incubated for two hours at room temperature with a polyclonal guinea pig anti-
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porcine insulin antibody (dilution 1:1000 in TBS) (Dako Cytomation). Thereafter 
slides were washed in TBS buffer for ten minutes, followed by an incubation step with 
horseradish peroxidase conjugated polyclonal rabbit anti-guinea pig IgG (dilution 
1:50 in TBS buffer containing 5% (vol/vol) porcine serum) for one hour. The slides 
were washed again in TBS buffer for ten minutes and immunoreactivity was 
visualized using 3,3´ diaminobenzidine tetrahydrochloride dehydrate (Sigma-Aldrich) 
as chromogen and 1% hydrogen peroxide as substrate. Mayer’s hemalaun solution 
was used for counterstaining. Tissue sections were then dehydrated in an ascending 
alcohol series, cleared in xylene and mounted under coverslips using Eukitt®. 
Specificity controls included substitution of primary antisera with nonimmune serum 
and omission of the secondary antiserum. 
 
3.3.9 Statistics 
All data are presented as means ± SEM. The statistical significance of differential 
findings between groups was determined using the Mann-Whitney-U-Test while 
differential findings within one group (group of control or transgenic animals) were 
evaluated using the Wilcoxon-Test. Both tests were applied in combination with an 
exact test procedure because of the small sample size (SPSS 15.0). P values less 
than 0.05 were considered significant. 
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4 Results 
4.1 Generation and genotyping of GIPRdn transgenic pigs 
To generate GIPRdn transgenic pigs, a gene transfer technology based on lentiviral 
vectors was used. The lentiviral construct is composed of the human dominant-
negative GIPR under control of the rat insulin 2 (Ins2) gene promoter (RIP2). The 
dominant-negative GIPR as described in Figure 4.1 has an eight amino acid deletion 
(amino acid position 319-326/nucleotide position 955-978) and two additional point 
mutations (amino acid position 340/nucleotide position 1018-1020), leading to an 
amino acid exchange from alanine to glutamate (Ala Æ Glu) in the third intracellular 
loop which is known to be essential for further signal transduction (Harmar 2001; 
Cypess et al. 1999; Hallbrink et al. 2001; Salapatek et al. 1999; Takhar et al. 1996). 
This targeted mutation results in a sustained binding affinity of the ligand GIP but a 
loss of the ligands ability to induce further signal transduction (Herbach et al. 2005, 
Volz 1997). 
 
 
 
Figure 4.1:  Amino acid sequence of the human GIPR 
Amino acid sequence of the human seven transmembrane domain G-protein coupled GIPR 
including marked areas where targeted mutations have been inserted (eight amino acid 
deletion (green) and an amino acid shift (Ala Æ Glu, red) (courtesy of Dr. Nadja Herbach). 
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Lentiviral particles were injected into the perivitelline space of 113 pig zygotes 
(Figure 4.2), which were then transferred laparoscopically into the oviducts of three 
cycle synchronized recipient gilts (sow 1: 32 zygotes; sow 2: 31 zygotes, sow 3: 50 
zygotes). Nineteen piglets (17% of the transferred zygotes) were born. Genotyping 
by PCR using DNA obtained from ear punches revealed nine transgenic (47.3%) 
founder animals (4 female; 5 male) confirming the high efficiency of lentiviral 
transgenesis in large animals (Hofmann et al. 2003). Southern blot analysis using 
DNA from EDTA blood and a probe which hybridizes in the region of the rat insulin 2 
promoter sequence identified either one or two lentiviral integrants in the previously 
determined nine founder pigs (Figure 4.3) while no signal was detected in littermate 
control animals. 
 
 
 
Figure 4.2:  Injection of the lentiviral construct into the perivitelline space of a pig 
zygote (courtesy of Tamara Holy). 
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Figure 4.3:  Southern Blot analyses of GIPRdn transgenic and control animals of the 
F0- and F1-generation 
(A) Schematic illustration of the transgenic construct consisting of the human dominant-
negative GIPR (GIPRdn) under control of the rat insulin 2 gene promoter (RIP2); probe: probe 
used for southern blot analyses directed towards the RIP2 sequence; ApaI: restriction site of 
ApaI; (B) Southern blot analyses of ApaI digested genomic DNA from EDTA blood of GIPRdn 
transgenic pigs (tg) and littermate control (wt) animals of the F0- and the F1-generation; S: 
sire of the piglets shown in the Southern blot of the F1-generation; piglets of the F1-
generation show segregation of the two integration sites of their particular sire. 
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Figure 4.4:  Southern Blot analyses of GIPRdn transgenic and control animals of the 
F2-generation 
Southern blot analyses of ApaI digested genomic DNA from EDTA blood of all live-born 
GIPRdn transgenic pigs (tg) and littermate control (wt) animals of the F2-generation; probe 
used for the analyses is shown in Figure 4.3 A; Southern blot analyses of sire #91 and sire 
#09 of the F1-generation is shown in Figure 4.3. 
 
For further characterization of germ line transmission and expression of the LV-RIP2-
GIPRdn construct, two male founder animals (#50, #51) (see Figure 4.3) were mated 
to non-transgenic German Landrace-Swabian-Hall crossbred control females, and 
offspring were genotyped by PCR (Figure 4.5) as well as by Southern blot analysis. 
Southern blot analysis demonstrated segregation of the integrants according to 
Mendelian rules (Figure 4.3). To establish a F2-generation of GIPRdn transgenic pigs 
from both previously selected founder animals, two boars (#91; #09) (see Figure 4.3) 
of the F1-generation were mated to German Landrace-Swabian-Hall crossbred wild-
type sows. Transgenic offspring also were identified by PCR and Southern blot 
analysis (Figure 4.4). 
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Figure 4.5:  PCR analyses for identification of GIPRdn transgenic pigs and littermate 
control animals of the F1-generation 
(A/C) Transgene specific PCR analyses for the GIPRdn transgene of offspring from founder 
boar #50 (A) and founder boar #51 (C); tg: GIPRdn transgenic pigs; wt: littermate non-
transgenic control pigs; M: pUC Mix Marker 8; +: positive control (genomic DNA of a 
previously genotyped pig); -: negative control (aqua bidest.); (B/D) PCR using β-actin specific 
primers was performed of all samples to control DNA integrity; M: pUC Mix Marker 8; +: 
positive control (genomic DNA of a previously genotyped pig); -: negative control (aqua 
bidest.). 
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4.2 Inheritance 
Inheritance of the GIPRdn transgene is summarized in the following table: 
 
Table 4.1:  Inheritance of the GIPRdn transgene 
 
m (wt) m (tg) f (wt) f (tg) Total (tg) %
F1 # 50 (F0) 1 1 6 3 2 66.67
F1 # 51 (F0) 2 11 2 9 2 16.67
F2 # 91 (F1) 2 3 12 3 10 78.57
F2 # 09 (F1) 1 3 2 3 3 45.45
Offspring
Generation Transgenic sire Number of litters
 
 
4.3 Expression analysis of the GIPRdn transgene 
To demonstrate expression of GIPRdn mRNA, porcine islets of Langerhans were 
isolated from 12 to 13-month-old transgenic (n=3) and three non-transgenic littermate 
control animals (offspring of both founder boars) and analyzed by reverse 
transcriptase polymerase chain reaction (RT-PCR) specific for GIPRdn 
complementary DNA. For each pig, two RNA samples (400 ng of total RNA each) 
were reverse transcribed and cDNA was analyzed for the presence of the GIPRdn 
transcript by PCR. Positive signals were obtained for islets from all transgenic 
animals, but not for islets from non-transgenic littermates. Signals from cDNA of 
islets from GIPRdn transgenic pigs #97 and #10 were less intense than signals from 
pig #91. No signals were obtained from islets of transgenic offspring after omission of 
the RT step, demonstrating that expressed rather than integrated sequences were 
detected. In addition, all cDNA samples were analyzed for the presence of mRNA of 
the housekeeping gene β-actin in order to evaluate efficiency of reverse transcription. 
Positive signals could be detected for all cDNA samples although signals from the 
cDNA of islets from GIPRdn transgenic pigs #97 and #10 were less intense than 
signals from pig #91. This led to the assumption that the weaker signals obtained by 
amplification of GIPRdn transcripts from islets of pig #97 and #10 may be caused 
rather by less efficient reverse transcription or differential RNA quality than by 
different expression levels. Nevertheless differences between expression levels of 
the GIPRdn transgene of the individual pigs could also have contributed to the 
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difference in signal intensity because GIPRdn transgenic pigs #97 and #10 have one 
integration site while pig #91 has two integration sites of the transgene. 
 
 
Figure 4.6:  Analysis of transgene expression (GIPRdn) in isolated porcine islets of 
Langerhans by RT-PCR 
(A) GIPRdn RT-PCR of transgenic and non-transgenic littermate control animals; (B) β-actin 
RT-PCR used for confirmation of reverse transcription efficiency; M: pUC Mix Marker; -RT 
wt: minus RT wild-type pigs; -RT tg: minus RT GIPRdn transgenic pigs; wt: wild-type pigs 
(#96, #11, #12); tg: GIPRdn transgenic pigs (#10, #97, #91) of the F1-generation; +: positive 
control (genomic DNA of GIPRdn transgenic pig); -: negative control (aqua bidest.). 
 
4.4 Normal blood glucose and serum fructosamine levels in 
 GIPRdn transgenic pigs 
To evaluate effects of GIPRdn expression on glucose homeostasis, blood was 
collected from the ear vein with a small lancet in fed 28-day-old animals (before 
weaning) and in 18 hours fasted pigs from the age of 35 days up to 84 days on a 
weekly basis and thereafter in longer intervals until the pigs were 210 days old. No 
significant differences in blood glucose levels were detected in GIPRdn transgenic 
pigs compared to their non-transgenic littermate control animals at any point of time 
investigated (Figure 4.7 A). In both groups of animals, all fasting blood glucose 
concentrations determined were within or little below the reference range of blood 
glucose for pigs that ranges, dependent on the laboratory, approximately between 70 
and 115 mg/dl. 
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Serum fructosamine levels were analyzed in fed 20-day-old pigs (before weaning) as 
well as in fasted animals at 41, 62, 84 and 210 days of age. No obvious difference in 
serum fructosamine levels was detected between GIPRdn transgenic pigs and their 
non-transgenic littermate control animals at any point of time evaluated (Figure 4.7 
B). Nevertheless a small but constant rise in fructosamine levels with age was seen 
in both groups as has been previously reported (Larsen et al. 2001). 
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  Normal blood glucose and serum fructosamine levels in GIPRdn 
 and non-transgenic littermate control pigs 
nsgenic pigs (tg) show normal blood glucose and serum fructosamine levels 
to non-transgenic littermate control animals (wt); (A) blood glucose concentrations 
ay-old and fasted 35- up to 210-day-old GIPRdn transgenic pigs (tg) and non-
littermate control animals (wt); (B) serum fructosamine levels of fed 28-day-old 
41- up to 210-day-old GIPRdn transgenic (tg) and non-transgenic littermate control 
t); data are means ± SEM; n: number of animals investigated. 
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4.5 Impaired oral glucose tolerance in GIPRdn transgenic pigs 
The effects of impaired GIP signaling on oral glucose tolerance were evaluated by an 
oral glucose tolerance test performed in 5-month-old (20 weeks ± 1 week) transgenic 
pigs (n=5) and five littermate controls originating from founder boar #50 (#91, #93, 
#97) and #51 (#09, #10). After oral glucose challenge (2 g/kg body weight), 
transgenic pigs exhibited a distinct reduced insulin secretion as well as elevated 
glucose levels compared to their non-transgenic littermate controls (Figure 4.8). The 
decline of blood glucose levels after having reached a peak level was markedly 
decelerated in GIPRdn transgenic pigs. The area under the curve (AUC) for insulin 
was reduced to 49% (p<0.01) in transgenic pigs as compared to the controls. 
Furthermore, the AUC for glucose was 26% larger (p<0.05) in GIPRdn transgenic pigs 
than in their non-transgenic littermate controls (Figure 4.8). Thus, these findings 
clearly demonstrate a reduced oral glucose tolerance in GIPRdn transgenic pigs. 
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Figure 4.8:  Impaired oral glucose tolerance in GIPRdn transgenic pigs 
GIPRdn transgenic pigs (tg) show impaired glucose tolerance in an oral glucose tolerance test 
at 5 months of age versus non-transgenic littermate control animals (wt); (A) serum insulin 
levels; AUC insulin: area under the insulin curve; (B) blood glucose levels; AUC glucose: 
area under the glucose curve; data are means ± SEM; **: p<0.01 vs. control; *: p<0.05 vs. 
control; n: number of animals investigated. 
 
4.6 Impaired intravenous glucose tolerance in GIPRdn transgenic 
 pigs 
To investigate whether the expression of a GIPRdn not only affects oral glucose 
tolerance but also general glucose homeostasis, intravenous glucose tolerance tests 
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were performed in transgenic and control pigs at 10 months (45 weeks ± 2 weeks), 
7 months (28-36 weeks), and 8 weeks of age. The group of 10-month-old pigs 
included five transgenic pigs and four control animals of the F1-generation 
(originating from founder boars #50 and #51) while intravenous glucose tolerance of 
five 7-month-old GIPRdn transgenic and four control animals (originating from boar 
#91 of the F1-generation) of the F2-generation was investigated. In addition, 
intravenous glucose tolerance of six 8-week-old pigs (3 transgenic pigs originating 
from boar #91 of the F1-generation and three control pigs) of the F2-generation was 
analyzed. Concentrated 50% glucose solution (0.5 g/kg body weight (BW)) was 
infused as a bolus through the jugular vein catheter. 10-month-old GIPRdn transgenic 
pigs showed considerably reduced insulin release going along with a decelerated 
decline of blood glucose levels (Figure 4.9). The area under the insulin curve was 
52% smaller (p<0.05), the AUC for glucose 10% larger (p<0.05) in GIPRdn transgenic 
pigs than in their non-transgenic littermate controls (Figure 4.9). At 7 months of age, 
GIPRdn transgenic pigs also revealed markedly but not significantly reduced insulin 
levels as well as a decelerated decline of blood glucose levels (Figure 4.10). Looking 
at the individual insulin curves of all transgenic animals of this age group, one pig 
showed exorbitantly higher insulin levels than the rest of the group leading to the 
assumption that the determined mean as well as AUC for insulin might mask the 
actual reduction of insulin secretion in transgenic pigs compared to controls (Figure 
4.10 B). The area under the insulin curve was 10.2% smaller (p=0.142) in transgenic 
pigs but would have been 43.6% smaller when disregarding the previously 
mentioned animal. The AUC for glucose was visibly but not significantly larger 
(21.6%, p=0.096) in transgenic pigs compared to controls (Figure 4.10). In contrast, 
8-week-old transgenic pigs showed a visible but small reduction of serum insulin 
levels and almost no difference in serum glucose levels (Figure 4.11). Accordingly, 
the AUC for insulin was not significantly smaller (39.3%, p=0.355) in GIPRdn 
transgenic pigs compared to controls. The AUC for glucose was 1.7% smaller 
(p=0.498) in transgenic pigs (Figure 4.11). 
In summary, GIPRdn transgenic pigs showed an impaired glucose tolerance at 7 and 
10 month of age while 8-week-old animals only tended towards this phenotype 
indicating a progressive deterioration of intravenous glucose tolerance in GIPRdn 
transgenic pigs. Impaired intravenous glucose tolerance in older GIPRdn transgenic 
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pigs could not be explained by just a reduced incretin effect initiated by the 
expression of a GIPRdn because the incretin effect is by-passed when glucose is 
administered intravenously. This led to the assumption of effects additional to an 
impaired incretin effect caused by a defective GIPR signaling (see below). 
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Figure 4.9:  Impaired intravenous glucose tolerance in 10-month-old GIPRdn 
transgenic pigs 
Intravenous glucose tolerance test of 10-month-old GIPRdn transgenic pigs (tg) and non-
transgenic littermate control animals (wt); (A) serum insulin levels; AUC insulin: area under 
the insulin curve; (B) serum glucose levels; AUC glucose: area under the glucose curve; data 
are means ± SEM; n: number of animals investigated; *: p<0.05 vs. control. 
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Figure 4.10:  Impaired intravenous glucose tolerance in 7-month-old GIPRdn 
transgenic pigs 
Intravenous glucose tolerance test of 7-month-old GIPRdn transgenic pigs (tg) and non-
transgenic littermate control animals (wt); (A) serum insulin levels; AUC insulin: area under 
the insulin curve; (B) individual insulin curves; (C) serum glucose levels; AUC glucose: area 
under the glucose curve; data are means ± SEM; n: number of animals investigated. 
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Figure 4.11:  Tendency of impaired intravenous glucose tolerance in 8-week-old 
GIPRdn transgenic pigs 
Intravenous glucose tolerance test of 8-week-old GIPRdn transgenic pigs (tg) and non-
transgenic littermate control animals (wt); (A) serum insulin levels; AUC insulin: area under 
the insulin curve; (B) serum glucose levels; AUC glucose: area under the glucose curve; data 
are means ± SEM; n: number of animals investigated. 
 
4.7 Reduced insulin secretion capacity in GIPRdn transgenic pigs 
The fact that the expression of a dominant-negative GIPR led to impaired 
intravenous glucose tolerance in older pigs raised the question whether transgenic 
pigs would also show reduced insulin secretory capacity in response to a challenge 
with glucagon. This question was addressed by a glucagon stimulation test which is 
routinely used in human medicine to estimate the need of exogenous insulin in 
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diabetic patients (Goeke, 2002). In this case, the test was accomplished in five 10-
month-old GIPRdn transgenic pigs and four controls analogous to the intravenous 
glucose tolerance test (IVGTT). In response to the intravenous administration of 1 mg 
glucagon (GlucaGen®, Novo Nordisk), GIPRdn transgenic pigs exhibited a clearly 
visible reduction in insulin secretory capacity (Figure 4.12). The course of the glucose 
curve was slightly lower in GIPRdn transgenic pigs compared to their control group 
(Figure 4.12). The area under the insulin curve was 51% smaller (p=0.056), the AUC 
for glucose 9% smaller (p=0.175) in GIPRdn transgenic pigs than in their non-
transgenic littermate controls (Figure 4.12). These results demonstrate a reduced 
insulin secretion capacity as a consequence of GIPRdn expression in the pancreatic 
islets of transgenic pigs. 
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Figure 4.12:  Glucagon stimulation test indicating reduced insulin secretion capacity 
in GIPRdn transgenic pigs 
Glucagon stimulation test of 10-month-old GIPRdn transgenic pigs (tg) and non-transgenic 
littermate control animals (wt); (A) serum insulin levels; AUC insulin: area under the insulin 
curve; (B) serum glucose levels; AUC glucose: area under the glucose curve; data are 
means ± SEM; n: number of animals investigated; AUC insulin: p=0.056 vs. control; AUC 
glucose: p=0.175 vs. control. 
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4.8 Impaired insulinotropic action of GIP in GIPRdn transgenic pigs 
In order to clarify the effect of porcine GIP on insulin secretion in the presence of the 
GIPRdn, an intravenous glucose tolerance test (IVGTT) as well as an IVGTT in 
combination with application of GIP was performed in GIPRdn transgenic pigs and 
non-transgenic control animals at 7 months (28-36 weeks) and 8 weeks of age 
(animals originated from F1 boar #91). For this purpose, 20 pmol/kg BW of synthetic 
porcine GIP were administered intravenously after three minutes relative to a glucose 
load (0.5 g/kg BW). Seven-month-old GIPRdn transgenic pigs (n=3) revealed a clearly 
reduced insulin secretion after glucose stimulation (IVGTT) compared to their non-
transgenic control animals (n=4); (Figure 4.13 A). In response to stimulation with 
glucose + GIP, animals of both groups showed increased insulin secretion compared 
to glucose administration only, although the effect of GIP was considerably more 
potent in wild-type pigs. 
∆Insulin(max./1min.) (difference of the maximum insulin level and the insulin level 
determined at one minute after the intravenous glucose load) following stimulation 
with glucose and GIP was significantly higher in control animals (p<0.05) compared 
to GIPRdn transgenic pigs, while ∆Insulin(max./1min.) did not differ significantly between 
the two groups after stimulation with just glucose ndicating that the insulinotropic 
action of GIP is impaired in GIPRdn transgenic pigs (Figure 4.13 B). Correspondingly, 
the decline of glucose levels was delayed in transgenic pigs receiving only glucose 
compared to controls. GIP was able to reduce the AUC for glucose 20.1% (p=0.13) in 
wild-type pigs but only 12.3% in transgenic pigs (p=0.127). 
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Figure 4.13:  Impaired insulinotropic action of GIP in GIPRdn transgenic pigs 
Intravenous glucose tolerance test (IVGTT) and IVGTT in combination with application of 
synthetic porcine GIP in 7-month-old GIPRdn transgenic pigs (tg) and age-matched control 
animals (wt); (A) serum insulin levels (B) ∆Insulin(max./1min.) of serum insulin levels; (C) serum 
glucose levels; (D) AUC glucose: area under the glucose curve; (Gc) glucose; (G) glucose + 
GIP; data are means ± SEM; *: p<0.05 vs. control; n: number of animals investigated. 
 
GIPRdn transgenic pigs at 8 weeks of age showed a visible but not significant 
reduction of insulin secretion following stimulation with glucose compared to controls. 
The AUC for insulin was diminished 39.3% (p=0.355) in transgenic animals 
compared to non-transgenic controls (see also Figure 4.11). Exogenous GIP had the 
ability to enhance insulin secretion of wild-type pigs by 12 µU/ml on average 
considering ∆Insulin(max./1min.) while it was not able to enhance insulin secretion in 
GIPRdn transgenic pigs (Figure 4.14 B). However, looking at the insulin curve (Figure 
4.14 A) a small increase of insulin levels of transgenic pigs following stimulation with 
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glucose + GIP could be detected. ∆Insulin(max./1min.) of wild-type pigs following glucose 
stimulation was considered zero as all pigs had their maximum insulin level one 
minute after administration of the glucose load. 
The AUC for glucose after glucose stimulation did not show any difference between 
the two groups (Figure 4.14 C). Exogenous GIP reduced the AUC for glucose 5.4% 
(p=0.252) in control animals and 8.8% (p=0.247) in transgenic pigs (Figure 4.14 D). 
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Figure 4.14:  Minor impairment of the insulinotropic effect of GIP in GIPRdn transgenic 
pigs 8 weeks of age 
Intravenous glucose tolerance test (IVGTT) and IVGTT in combination with application of 
porcine GIP in 8-week-old GIPRdn transgenic pigs (tg) and control animals (wt); (A) serum 
insulin levels; (B) AUC insulin: area under the insulin curve; (C) serum glucose levels; (D) 
AUC glucose: area under the glucose curve; (Gc) glucose; (G) glucose + GIP; data are 
means ± SEM; n: number of animals investigated. 
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In conclusion, GIPRdn transgenic pigs show an impaired insulinotropic effect of GIP 
compared to non-transgenic control animals being more pronounced in 7-month-old 
pigs compared to animals at 8 weeks of age. 
 
4.9 Reduced insulin secretion in Exendin-4-stimulated older 
 GIPRdn transgenic pigs 
The insulinotropic action mediated by the GLP-1 receptor was evaluated by an 
Exendin-4 stimulation test. Exendin-4 is a naturally occurring, potent GLP-1 receptor 
agonist due to its resistance against dipeptidyl-peptidase 4 and the resulting long 
half-life. Glucose (0.5 g/kg BW) was administered intravenously either alone or in 
combination with synthetic Exendin-4 (10 pmol/kg BW). Following glucose 
administration, 7-month-old GIPRdn transgenic pigs demonstrated a visible but not 
significant reduction of insulin secretion compared to non-transgenic control animals 
which is related to one GIPRdn transgenic pig showing exorbitant higher insulin levels 
compared to the rest of the transgenic group (Figure 4.15 A; see also Figure 4.10 B). 
Exendin-4 potentiated insulin secretion in GIPRdn transgenic pigs to a lesser extent 
than in controls but to a higher extent than after glucose + GIP stimulation (Figure 
4.15 A; Figure 4.13 A). Comparison of ∆Insulin(max./1min.) between GIPRdn transgenic 
pigs and non-transgenic controls revealed a distinct difference for stimulation with 
glucose + Exendin-4 (p=0.052) but only a minimal difference after having received 
only glucose (Figure 4.15 B). Additionally, the AUC for glucose following stimulation 
with glucose + Exendin-4 was significantly larger (p<0.05) in transgenic pigs, while 
no significant difference (p=0.145) was observed after glucose stimulation (Figure 
4.15 D). Exogenous Exendin-4 had the ability to reduce the AUC for glucose 24.5% 
in control animals but only 9.3% in GIPRdn transgenic pigs (Figure 4.15 D). 
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Figure 4.15:  Reduced insulin secretion induced by glucose + Exendin-4 application in 
GIPRdn transgenic pigs 
Intravenous glucose tolerance test (IVGTT) and IVGTT in combination with application of 
synthetic Exendin-4 in 7-month-old GIPRdn transgenic pigs (tg) and control animals (wt); (A) 
serum insulin levels; (B) ∆ Insulin(max./1min.) of serum insulin levels; (C) serum glucose levels; 
(D) AUC glucose: area under the glucose curve; (Gc) glucose; (E) glucose + Exendin-4; data 
are means ± SEM; *: p<0.05 vs. control; n: number of animals investigated. 
 
In contrast, Exendin-4 potentiated insulin secretion in 8-week-old transgenic pigs to 
the same extent as in non-transgenic control animals (Figure 4.16 A). Following 
glucose + Exendin-4 stimulation, ∆ Insulin(max./1min.) of transgenic and wild-type pigs 
rose by 69.9 µU/ml (p=0.124) and 80.5 µU/ml (p=0.249) compared to glucose 
stimulation, respectively (Figure 4.16 B). Insulin levels after glucose stimulation were 
visibly but not significantly reduced in GIPRdn transgenic pigs compared to controls 
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(Figure 4.16 A). Accordingly, serum glucose concentrations were equal between the 
groups after glucose and glucose + Exendin-4 stimulation (Figure 4.16 C). Exendin-4 
was able to reduce the AUC for glucose 13.2% and 14.5% in GIPRdn transgenic pigs 
and non-transgenic controls, respectively (Figure 4.16 D). 
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Figure 4.16:  Normal insulin secretion following intravenous Exendin-4 application in 
8-weeks-old GIPRdn transgenic pigs 
Intravenous glucose tolerance test (IVGTT) and IVGTT in combination with application of 
synthetic Exendin-4 in 8-week-old GIPRdn transgenic pigs (tg) and control animals (wt); (A) 
serum insulin levels; (B) ∆ Insulin(max./1min.) of serum insulin levels; (C) serum glucose levels; 
(D) AUC glucose: area under the glucose curve; (Gc) glucose; (E) glucose + Exendin-4; data 
are means ± SEM; n: number of animals investigated. 
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To summarize, insulin secretion following stimulation with glucose + Exendin-4 is 
equal in GIPRdn transgenic and control pigs at 8 weeks of age but reduced in 7-
month-old transgenic animals compared to controls. 
 
4.10 Reduced islet and β-cell mass in older GIPRdn transgenic pigs 
In order to clarify whether impaired intravenous glucose tolerance, reduced insulin 
secretion capacity shown in a glucagon stimulation test as well as reduced insulin 
secretion following glucose + Exendin-4 stimulation in older GIPRdn transgenic pigs 
might be caused by alterations in islet structure and/or islet integrity, quantitative islet 
isolation as well as quantitative stereological analyses were performed in 12 to 13-
month-old GIPRdn transgenic pigs (n=3) and three age matched non-transgenic 
littermate control animals of the F1-generation originating from founder boar #50 and 
#51. To determine these parameters each organ was divided into two portions along 
a clearly defined anatomical structure (see Figure 3.6). The left pancreatic lobe was 
processed for islet isolation using a protocol which is routinely used to isolate 
pancreatic islets for transplantation purposes (Krickhahn et al. 2001) while the 
remnant organ was used for quantitative stereological analyses. 
 
4.10.1 Isolation of islets of Langerhans  
The six isolations from control and transgenic pancreata were performed without any 
technical problems. The isolation endpoint in both groups ranged between 20 and 25 
minutes, a time frame that was previously determined for the specific batches of 
collagenase and neutral protease. The results, summarized in Table 4.2, show 
significant differences in islet numbers, i.e., endocrine cell mass, between the two 
groups (p<0.05). GIPRdn transgenic pigs contained approximately fourteen times less 
islets in their pancreas compared to the controls. Vitality and purity of islets was 
identical in both groups (Table 4.2) and islets of both groups showed a tendency to 
fragment (not documented). Dithizone stained samples (100 µl each) obtained after 
the digest of the pancreas of each animal were qualitatively assessed and revealed a 
clearly visible difference between transgenic and non-transgenic pigs regarding islet 
 94
Results 
size but especially islet number. Samples of GIPRdn transgenic pigs showed fewer 
islets and islets were smaller in size than samples of control animals. 
 
 A B
 
Figure 4.17:  Representative dithizone stained samples originating from the left 
pancreatic lobe of a pancreas from a transgenic and a wild-type pig after completion 
of the digest 
Qualitative assessment of digested samples from the pancreas of control pigs (A) show 
several islets as well as islet fragments per field of view; samples from GIPRdn transgenic 
pigs (B) show few islet fragments per field of view; scale bar 200 µm. 
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Table 4.2:  Islet isolation results using the left pancreatic lobes of non-transgenic 
(wt) and GIPRdn transgenic pigs (n=3 in each group) 
Type 
of Pig 
Total IEQ 
Purified 
Total IEQ/ 
g Organ 
Islet 
Purity (%)* 
Islet 
Vitality (%)* 
wt #1 72,673 889.71 95 95 
wt #2 90,260 1519.53 85 80 
wt #3 71,658 1119.66 85 80 
mean ± SEM 78,197 ± 6,038 1176.23 ± 
184 
88.3 ± 3.33 85 ± 5.0 
     
tg #1 4,053 50.66 85 80 
tg #2 6,026 81.76 85 80 
tg #3 6,240 89.14 85 80 
mean ± SEM 5,439 ± 696 73.85 ± 
11.79 
85 80 
 
IEQ: islet equivalent (islet of 150 µm in size); * estimation by two independent 
individuals after microscopic inspection. 
 
In addition, qualitative assessment of dithizone stained frozen sections from samples 
of all left pancreatic lobes used for islet isolation also revealed a clearly visible 
difference between the two groups (Figure 4.19). While small and medium-sized 
islets could be detected in great quantities in non-transgenic pigs, dithizone stained 
frozen sections of transgenic pigs showed only few small and almost none medium-
sized islets. Frozen sections immunohistochemically stained for insulin also revealed 
islets of Langerhans less in number and smaller in size in GIPRdn transgenic animals 
compared to the control group (Figure 4.18). Thus, these results are consistent with 
low islet recovery in GIPRdn transgenic pigs. 
 96
Results 
 
 
Figure 4.18:  Reduced islet number and islet size in GIPRdn transgenic pigs compared 
to non-transgenic littermate controls 
Immunohistochemistry for insulin of frozen sections from tissue samples of the left pancreatic 
lobe; (A/B/C) non-transgenic control pigs #96, #11, #12 of the F1-generation; (D/E/F) GIPRdn 
transgenic pigs #97, #10, #91 of the F1-generation; magnification 4 x. 
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Figure 4.19:  Reduced islet number and islet size in GIPRdn transgenic pigs compared 
to non-transgenic littermate controls 
Dithizone stained frozen sections from tissue samples of the left pancreatic lobe; (A/B/C) 
non-transgenic control pigs #96, #11, #12 of the F1-generation; (D/E/F) GIPRdn transgenic 
pigs #97, #10, #91 of the F1-generation; magnification 10 x. 
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4.10.2 Quantitative stereological analyses 
The findings of the quantitative islet isolation procedures were confirmed by 
quantitative stereological investigations, using the remnant pancreas. Previous 
qualitative assessment of the organ as well as of H&E stained sections revealed that 
gross morphology and histological appearance of the exocrine pancreas was 
unchanged in transgenic pigs. In H&E stained sections, pancreatic islet profiles of 
GIPRdn transgenic pigs appeared to be smaller in size but especially in number. In 
addition, distinct differences between the two investigated animal groups were 
discovered in quantitative stereological parameters. The total islet volume (V(Islet,Pan)) 
was significantly lower (72%; p<0.05) in transgenic pigs compared to non-transgenic 
littermate control animals (Figure 4.20 A). The same was true for the volume density 
of the islets in the pancreas (Vv(Islet/Pan)) (72% reduction in transgenic pigs; p=0.05); 
(Figure 4.20 B). Also, the total volume of “islet-associated” β-cells (V(β-cell,Islet)) was 
considerably reduced (75%; p<0.05) in transgenic pigs (Figure 4.20 C). The volume 
density of β-cells in the islets (Vv(β-cell/Islet)) was diminished by 11% (p=0.052) in the 
group of transgenic pigs compared to the controls (Figure 4.20 D). The total volume 
of the β-cells including isolated β-cells (V(β-cell,Pan)) was also significantly reduced 
(71%, p<0.05) in GIPRdn transgenic pigs compared to their non-transgenic littermate 
controls (Figure 4.20 E). A clear reduction could also be detected for the volume 
density of the β-cells in the pancreas (Vv(β-cell/Pan)) of transgenic pigs (71%, p<0.05) 
(Figure 4.20 F). In contrast, the total volume of isolated β-cells (single insulin positive 
cells and small β-cell clusters) in the pancreas (V(isoβ-cell,Pan)), a parameter indicating 
islet neogenesis, was not different between the two groups (p=0.199) (Figure 4.20 
G). According to that, the volume density of isolated β-cells in the pancreas (Vv(isoβ-
cell/Pan)) didn’t reveal any difference between the two groups (p=0.198) (Figure 4.20 
H). Representative pancreatic sections from GIPRdn transgenic pigs and control 
littermates are shown in Figure 4.21 illustrating the morphometric findings. These 
data demonstrate a marked reduction of pancreatic islet and β-cell mass in 
transgenic pigs expressing a GIPRdn in their pancreatic islets, however there was no 
clear evidence for disturbed islet neogenesis. 
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Figure 4.20:  Reduced islet and β-cell mass in GIPRdn transgenic pigs 
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Quantitative stereological analyses of the pancreas of transgenic (tg) and control (wt) pigs; 
(A/B) Total volume (V(Islet,Pan)) and volume density (Vv(Islet/Pan)) of the islets in the pancreas; 
(C/D) Total volume (V(β-cell,Islet)) and volume density (Vv(β-cell/Islet)) of the β-cells in the islets; 
(E/F) Total volume (V(β-cell,Pan)) and volume density (Vv(β-cell/Pan)) of the β-cells in the pancreas; 
(G/H) Total volume (V(iso β-cell,Pan)) and volume density (Vv(iso β-cell/Pan)) of isolated β-cells in the 
pancreas; data are means ± SEM; n: number of animals investigated; *: p<0.05 vs. control. 
 
 
Figure 4.21:  Representative pancreatic sections from GIPRdn transgenic pigs and 
control littermates 
Immunohistochemistry for insulin of pancreatic sections from GIPRdn transgenic pigs (B/D) 
and non-transgenic littermate controls (A/C) illustrating the morphometric findings: GIPRdn 
transgenic pigs show islet profiles reduced in numerical area density; (A/B) magnification 
2.5 x; scale bar 200 µm; (C/D) magnification 10 x; scale bar 200 µm. 
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5 Discussion 
This work included the generation and analysis of the first large animal model 
characterized by a defective GIPR signaling, which is a consistent finding in type 2 
diabetic patients with hitherto unclear pathogenetic relevance. 
 
5.1 Generation of GIPRdn transgenic pigs by lentiviral gene 
 transfer 
For the generation of this pig model, a gene transfer technology based on lentiviral 
vectors was used. This technique was chosen since recently a reproducibly high 
efficiency of lentviral gene transfer into porcine and bovine oocytes and zygotes was 
shown (Hofmann et al. 2003). In general, the efficiency of DNA microinjection, the 
most widespread technology to generate transgenic animals (Clark & Whitelaw 
2003), is low. In the mouse, approximately 2.6% of transgenic offspring per injected 
& transferred embryos can be obtained while in the pig the efficiency is even lower 
ranging at 0.9% (Wall, 1996). In contrast, generation of transgenic pigs carrying the 
green fluorescent protein (GFP) gene under the control of the ubiquitously 
expressing phosphoglycerate kinase promoter (PGK) by lentiviral gene transfer 
revealed 70% of the born animals (13.1% of infected & transferred embryos) being 
transgenic (Hofmann et al. 2003). Generation of GIPRdn transgenic pigs using the 
same lentiviral vector backbone based on the human immunodeficiency virus-1 (HIV-
1) was little less efficient. Here, 47.3% of all born pigs were transgenic (8% of 
infected & transferred embryos). Another group that generated transgenic pigs on the 
basis of an equine infectious anemia virus derived vector achieved 92% of transgenic 
pigs (31% of the transferred embryos) (Whitelaw et al. 2004). Lentiviral vectors 
integrate as a single-copy per integration site, however, animals can carry more than 
one lentiviral integrant. In the two studies previously mentioned, founder pigs 
revealed one up to twenty (mean 4.6 ± 0.9) lentiviral integrants (Hofmann et al. 2003) 
or one to five integrants (Whitelaw et al. 2004) by Southern blot analyses. Transgene 
copy number was determined in seven GIPRdn transgenic founder animals (two 
animals died shortly after birth and were not analyzed for transgene integration but 
were determined transgenic by PCR) and revealed either one or two integration sites. 
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Germline transmission as well as segregation of the integration sites according to the 
Mendelian rules could be determined by Southern blot analyses of pigs of the F1- 
and F2-generation originating from two founder boars (#50 and #51). 
The transgenesis rate as well as the number of integration sites was lower in GIPRdn 
transgenic pigs as it has been previously reported for pigs generated by lentiviral 
gene transfer (Hofmann et al. 2003; Whitelaw et al. 2004). This could be related to a 
lower virus titer of the LV-RIP2-GIPRdn virus that was used. The yield of different 
virus preparations is subject to fluctuation and can vary from 5x108 to 2x1010 
infectious units/ml (Hofmann, personal communication). The injection volume that 
can be transferred into the perivitelline space is limited. Thus, a lower virus titer leads 
to injection of a lower total number of infectious particles. However, this suspicion 
cannot be verified or ruled out in this case as the titer of LV-RIP2-GIPRdn was not 
determined. The biological virus titer of lentiviral vectors carrying the green 
fluorescent protein can be determined by Fluorescence Activated Cell Sorting 
(FACS) analyses of infected cells. The virus titer of LV-RIP2-GIPRdn could have been 
evaluated by quantitative determination of viral proteins like the reverse transcriptase 
or p24, a major core protein of the HI-virus, using an ELISA. But this technique also 
accounts for inactive particles leading to a less accurate result. 
A lower transgenesis rate with 12% of the born pigs being transgenic (2.3% of the 
transferred embryos) coming along with a lower virus titer as compared to the 
lentiviral construct LV-PGK-GFP (described above) was reported in GFP transgenic 
pigs using the skin-specific human keratin K14 gene promoter (Hofmann et al. 2003; 
Hofmann 2006a). Another possibility that would explain the reduced integration 
efficiency of LV-RIP2-GIPRdn is the difficulty to control the volume of virus delivered 
into the perivitelline space during the injection (Lois et al. 2002). It has been reported 
in mice, that incubation of denuded embryos in a lentiviral suspension allows better 
control of the number of proviral integration sites per genome (Lois et al. 2002). 
However, this method was found to be not practical for the use in pigs due to the high 
embryonic losses after denudation. 
In summary, generation of GIPRdn transgenic pigs by lentiviral gene transfer was 8-
fold more efficient as compared to the average success rates of pronuclear DNA 
microinjection. GIPRdn transgenic founder pigs showed one or two integration sites of 
the transgene and germline transmission was proven. 
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5.2 Expression of the GIPRdn transgene 
Expression of the transgene was analyzed in isolated porcine islets of Langerhans 
from GIPRdn transgenic pigs by RT-PCR. Pigs of the F1-generation, 12 to13-months 
of age, originating from founder boar #50 and #51 and carrying either one or two 
integration sites were tested. Expression of the GIPRdn transgene could be 
determined in all transgenic animals although the intensity of the signals was not 
equal in all three animals evaluated. Signals from cDNA of islets from GIPRdn 
transgenic pig #97 and #10 were less intense than signals from pig #91. As the same 
result was obtained for analysis of the presence of β-actin mRNA to control reverse 
transcription efficiency, it was presumed that the weaker signals obtained by 
amplification of GIPRdn transcripts from islets of pig #97 and #10 may be caused 
rather by less efficient reverse transcription or differential RNA quality than by 
different expression levels. However, a correlation between proviral copy number and 
transgene expression levels has been reported previously (Hofmann et al. 2003; Lois 
et al. 2002). Thus, different expression levels of the GIPRdn transgene between the 
individual pigs could have contributed to the difference in signal intensity because 
GIPRdn transgenic pigs #97 and #10 have one integration site while pig #91 has two 
integration sites of the transgene. 
However, the presence of GIPRdn transcripts does not necessarily mean that the 
GIPRdn transgene is expressed on the protein level. Unfortunately, there is no 
antibody available which can differentiate between the endogenous GIPR and the 
GIPRdn. However, the phenotypic changes observed in GIPRdn transgenic pigs are 
indicative of the presence of the GIPRdn protein. 
One integration site of founder boar #50 did not result in offspring showing an 
aberrant phenotype compared to controls although GIPRdn mRNA could be detected 
in the islets of Langerhans of one 5-month-old animal by RT-PCR (data not shown). 
This might be related to a low expression level and DNA-hypermethylation as has 
been previously described (Hofmann et al. 2006). 
The results of expression analyses by RT-PCR indicate that the heterologous rat 
insulin 2 promoter is sufficient to direct the expression of GIPRdn mRNAs in the 
pancreatic islets of pigs. It was previously shown that expression of the GIPRdn 
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transgene under control of the rat insulin 2 promoter resulted in a distinct diabetic 
phenotype and disturbed development of the endocrine pancreas in mice (Herbach 
et al. 2005); (see below). 
 
5.3 Normal blood glucose and serum fructosamine levels in 
 GIPRdn transgenic pigs 
Blood glucose as well as serum fructosamine levels were evaluated to detect the 
presence of a diabetic phenotype in GIPRdn transgenic pigs. Blood glucose levels 
were determined in fed 28-day-old animals (before weaning) and in 18 hours fasted 
pigs from the age of 35 days up to the age of 210 days. Blood was collected from the 
ear vein in order to reduce the amount of stress associated with the blood collection 
procedure as blood glucose levels are responsive to stress. 
No significant differences in blood glucose levels could be determined in GIPRdn 
transgenic pigs compared to their non-transgenic littermate control animals at any 
point of time investigated. Also, fasting blood glucose concentrations were always 
within or little below the reference range of blood glucose for pigs. 
In addition, serum fructosamine levels were determined because this parameter is 
not responsive to stress and shows long-term glucose control. The analysis of serum 
fructosamine levels was preferred to the determination of HbA1c because porcine 
erythrocytes contain only small intracellular glucose concentrations. Thus, porcine 
hemoglobin contains few glycosylated components (HbA1c) due to a limited 
permeability of erythrocytes to glucose (Higgins et al. 1982). Therefore HbA1c should 
not be considered as an appropriate indicator of glycemia in pigs as it is used in 
humans (Gabbay et al. 1977; Koenig et al. 1976). While fructosamine levels show 
glycemic control of the previous one to three weeks (dependent on the half-life of 
albumin), HbA1c levels provide information of glucose control of the past ~120 days 
(dependent on the half-life of erythrocytes) which means that fructosamine levels are 
more sensible to changes in glucose control. In GIPRdn transgenic pigs no obvious 
difference of serum fructosamine levels was detected compared to their non-
transgenic littermate control animals at any point of time evaluated. Fructosamine 
levels were similar to those previously reported for the pig and showed a small but 
consistent rise with age in both groups (Larsen et al. 2001). At this point it can be 
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stated that GIPRdn transgenic pigs do not develop an overt diabetic phenotype until 
an age of at least 15 months. 
 
5.4 Impaired oral glucose tolerance in GIPRdn transgenic pigs 
The first important functional consequence of GIPRdn expression in the pancreatic 
islets of transgenic pigs was reduced oral glucose tolerance associated with reduced 
initial insulin secretion noted in 5-month-old pigs. This observation is fully in line with 
the incretin concept. The findings that GIPRdn transgenic pigs exhibit a normal 
glucose metabolism in the fasting state, indicated by normal fasting blood glucose 
and serum insulin levels, but abnormal glucose regulation and β-cell function in the 
postprandial state could also be observed in GIPR-/- mice (Miyawaki et al. 1999). 
Additionally, administration of a GIPR antibody to healthy mice before oral glucose 
challenge led to no change in fasting blood glucose showing that the incretin 
hormone GIP predominantly acts in the postabsorptive state (Baggio et al. 2000). 
These data are similar to impaired oral glucose tolerance observed in humans. Here, 
the initial insulin secretion within the first 30 minutes after nutrient ingestion is 
markedly decreased compared to subjects with normal glucose tolerance which 
leads to an elevated postprandial rise in glycemia (Leahy 2005). The first phase of 
insulin secretion seems to play a key role during food ingestion to prime the tissues 
for the incoming nutrients. It was reported that disruption of the first phase of insulin 
secretion in healthy humans causes glucose intolerance (Calles-Escandon & 
Robbins 1987; Luzi & DeFronzo 1989) while in type 2 diabetic patients, the first 
phase was improved following a period of intense glucose control (Bruce et al. 1988; 
Vague & Moulin 1982). Considering impaired intravenous glucose tolerance detected 
in 7-month-old and 10-month-old GIPRdn transgenic pigs (see below), it cannot be 
excluded that incipient reduction of islet/β-cell mass in 5-month-old transgenic pigs 
could have contributed to impaired oral glucose tolerance in addition to the impaired 
incretin effect caused by the expression of a GIPRdn in the islets of Langerhans. 
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5.5 Impaired intravenous glucose tolerance in older GIPRdn 
 transgenic pigs 
Intravenous glucose tolerance tests were performed in pigs of three age groups: 8 
weeks, 7 months and 10 months of age. At 10 month of age GIPRdn transgenic pigs 
showed impaired intravenous glucose tolerance clearly determined by a significantly 
decelerated decline of glucose levels along with a significantly reduced insulin 
secretion. Unlike older pigs, 8-week-old animals did not show significant differences 
in glucose and insulin levels following an intravenous glucose load. Four out of five 7-
month-old GIPRdn transgenic pigs revealed significantly reduced insulin levels 
compared to control pigs, indicating impaired intravenous glucose tolerance. 
Surprisingly, the fifth transgenic pig showed exorbitantly higher insulin levels than the 
rest of the group. This observation may be related to individual differences 
concerning the beginning/progression of the reduction of islet/β-cell mass or glucose 
tolerance in general. However, this might not explain the large difference in insulin 
levels. Surprisingly, glucose levels of this pig were higher than glucose levels of the 
other transgenic pigs. 
Irrespective of the results in 7-month-old GIPRdn transgenic pigs, a progressive 
deterioration of intravenous glucose tolerance with age was detected that may 
correlate with a progressive decline of islet/β-cell mass. In general, impaired 
intravenous glucose tolerance cannot be explained by just an impaired incretin effect 
initiated by the expression of a GIPRdn because the incretin effect is bypassed by 
intravenous administration of a glucose load. 
In contrast, no difference of blood glucose levels of GIPR-/- mice following an 
intraperitoneal glucose tolerance test which is comparable to an IVGTT was found 
compared to controls (Miyawaki et al. 1999) (see below). However, release of incretin 
hormones can be stimulated to some degree due to the rise of glucose levels in the 
portal vein following an intraperitoneal glucose load (Gallwitz & Schmidt 1997). 
 
5.6 Reduced insulin secretion capacity in GIPRdn transgenic pigs 
Glucagon stimulation tests were performed in 10-month-old pigs in order to elucidate 
a possible impairment of insulin secretion capacity in GIPRdn transgenic pigs. This 
test has been previously used in diabetic humans to evaluate the remaining function 
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of the β-cell and therefore estimate the need for exogenous insulin (Faber & Binder 
1977; Goeke 2002). GIPRdn transgenic pigs showed a borderline significant reduction 
of insulin secretion in response to glucagon administration compared to littermate 
non-transgenic control animals. As the above mentioned impairment in intravenous 
glucose tolerance, this result points to alterations in islet structure and/or islet 
integrity, but could also be related to a disturbance of insulin secretion or a 
combination of both. The application of 1 mg glucagon might not have led to maximal 
insulin secretion considering the fact that stimulation with Exendin-4 led to notably 
higher insulin levels in transgenic pigs as well as in controls. Thus, application of 
more than 1 mg of glucagon might have resulted in an even more pronounced 
difference in insulin secretion capacity between GIPRdn transgenic pigs and controls. 
The slightly reduced serum glucose levels of transgenic pigs may be related to less 
glycogen storage in the liver of transgenic pigs compared to controls. Normally, 
insulin is a potent suppressor of hepatic glucose production. Thus, insulin deficiency 
as well as insulin resistance leads to increased glycogenolysis and gluconeogenesis 
associated with increased hepatic output (Berger, 2000). In GIPRdn transgenic pigs, 
insulin deficiency can be expected due to defective insulin secretion and/or reduced 
islet/β-cell mass. This could explain the slightly lower glucose levels in GIPRdn 
transgenic pigs following stimulation with glucagon. 
 
5.7 GIP/Exendin-4 stimulation test 
GIP/Exendin-4 stimulation tests were performed in animals at 7 months and 8 weeks 
of age to evaluate whether a specific disturbance of GIPR signaling was achieved in 
transgenic pigs expressing a GIPRdn in their pancreatic islets. Stimulation with only 
glucose served as a baseline for serum glucose and serum insulin levels. An 
intravenous glucose load only resulted in impaired insulin secretion of 7-month-old 
pigs but not of 8-week-old pigs (see intravenous glucose tolerance test). Exogenous 
GIP was able to stimulate insulin secretion of GIPRdn transgenic and control pigs of 
both age groups, however this effect was less pronounced in transgenic animals than 
in controls. The difference of insulin levels following glucose + GIP stimulation 
between transgenic and control animals turned out to be smaller in the 8-week-old 
group compared to the 7-month-old group. A functional endogenous GIPR is still 
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present in GIPRdn transgenic pigs although the endogenous GIPR has to compete 
with the GIPRdn for the ligand GIP. Therefore a residual function of GIP-related 
insulin secretion after exogenous GIP stimulation can be expected. This is a different 
situation than in GIPR-/- mice. According to expectations, in vitro stimulation of 
isolated islets of Langerhans from GIPR-/- mice did not show residual GIP function 
(Miyawaki et al. 1999). 
In addition, application of supraphysiological GIP levels leads to partial binding of 
GIP to the GLP-1 receptor that is intact in GIPRdn transgenic pigs resulting in 
additional insulin secretion following GIP + glucose stimulation (Brubaker & Drucker 
2002; Wheeler et al. 1993). Exendin-4, a potent GLP-1 receptor agonist, binds to an 
intact GLP-1 receptor in controls as well as in transgenic pigs. Normal insulin levels 
following stimulation with glucose (IVGTT) and glucose + Exendin-4 in 8-week-old 
transgenic pigs compared to control animals are indicative for a normal insulin 
secretion capacity and/or islet/β-cell mass. In contrast, stimulation with glucose 
(IVGTT) and glucose + Exendin-4 led to a diminished insulin secretion in 7-month-old 
GIPRdn transgenic pigs which is most likely the consequence of an already existing 
reduction in islet/β-cell mass and/or altered insulin secretion capacity with this age. 
Thus, potentiation of glucose-stimulated insulin secretion by exogenous GIP 
administration can yield higher insulin levels in 8-week-old (presumably normal 
islet/β-cell mass) than in 7-month-old GIPRdn transgenic pigs, explaining the smaller 
difference of insulin levels in the younger animals compared to controls. Also, 
Exendin-4 binds the GIPR to some degree following administration of high Exendin-4 
concentrations (Gremlich et al. 1995; Brubaker & Drucker 2002). Thus, its effect may 
be partially reduced by the expression of the GIPRdn. Anyhow, binding of Exendin-4 
to the GIPRdn could not visibly reduce insulin secretion because in 8-week-old 
transgenic pigs, insulin secretion following glucose + Exendin-4 stimulation was 
preserved. Due to the small number of animals investigated as well as moderate 
variations of insulin levels in the control group all previously described effects are 
clearly visible but not all of them reach statistical significance. 
In summary, specificity of the dominant-negative approach used for to generate this 
animal model was proven by both the reduced potentiation of insulin secretion 
following stimulation with exogenous GIP in transgenic pigs of both age groups and 
the fully preserved effect of Exendin-4 in GIPRdn transgenic pigs at 8 weeks of age. 
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However, due to the small number of animals investigated as well as variation of 
insulin levels of the control group, not all parameters reached statistical significance. 
Besides the application of a larger animal group, some other methods of resolution 
might be possible. An option to overcome the short half-life of GIP as well as binding 
of GIP to the GLP-1 receptor could be the infusion of physiological levels of 
exogenous GIP over a longer period of time instead of bolus administration. 
Additionally, stimulation studies with GIP and Exendin-4 using isolated porcine islets 
of Langerhans might be valuable. That way studies can be performed in a highly 
standardized manner. Freshly isolated islets in pigs but especially in rodents are 
commonly used to study the responsiveness of glucose and direct activators of signal 
transduction cascades. But it has to be taken into account that the acute secretory 
response may be blunted likely due to receptor damage by collagenase (Siegel & 
Creutzfeldt 1985). This might be especially problematic in the pig because only 25% 
of all porcine islets within the pancreas are well capsulated (Ulrichs et al. 1995) 
making the rest of them more susceptible to damage by collagenase digestion. 
 
5.8 Reduced islet and β-cell mass in GIPRdn transgenic pigs 
The suspected reduction of islet/β-cell mass of GIPRdn transgenic pigs was proven by 
quantitative islet isolation, using the left pancreatic lobe, as well as morphometric 
analyses of the remnant organ. Recovery of islet equivalents (i.e. islet 150 µm in 
diameter) in transgenic pigs was fourteen times less than in controls. Some criteria 
underline the significance of this result. It is well known that the number of islets vary 
widely between different breeds (Ulrichs et al. 1995). This factor of variance was 
reduced by the use of littermates for the analyses. The isolation method was highly 
standardized as it is routinely used for transplantation purposes. This is indicated 
among other things by the fact that digestion endpoints ranged only between 20-25 
minutes, vitality and purity of the isolated islets were identical in both groups and 
variation of the recovery of total IEQ and accordingly total IEQ/g organ was minimal 
within one group. Dithizone stained frozen sections as well as sections 
immunostained for insulin originating from the left pancreatic lobe confirmed the 
isolation result. 
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Qualitative assessment of the remnant organ as well as of H&E stained sections 
revealed no abnormalities of gross morphology and histological appearance of the 
exocrine pancreas in transgenic pigs. Quantitative stereological analyses of the 
remnant organ were carried out using unbiased, model-independent stereological 
methods (Gundersen et al. 1988; Gundersen & Jensen 1987; Kroustrup & 
Gundersen 1983). The expression of a dominant-negative GIPR in pancreatic islets 
was found to be associated with a severe reduction of the total volumes as well as 
volume densities of islets and β-cells within the pancreas. In contrast, no significant 
difference was seen in the total volume and volume density of isolated β-cells (single 
insulin positive cells and small β-cell clusters) between GIPRdn transgenic pigs and 
control animals. Presence of isolated β-cells is indicative for islet neogenesis (Petrik 
et al. 1999; Xu et al. 1999). Thus, there was no clear evidence for disturbed islet 
neogenesis in GIPRdn transgenic pigs. 
In summary, severe reduction of islet/β-cell mass could be determined by two 
different approaches, using one organ respectively. In the pig, the β-cell is 
predominant in both the ventral and the dorsal pancreas while α-cells exist mainly in 
the dorsal pancreas and pancreatic polypeptide containing cells are almost 
exclusively located in the ventral pancreas (Wieczorek et al. 1998; Jay et al. 1999). 
Somatostatin staining cells (δ-cells) also were located in the dorsal and ventral 
pancreas (Jay et al. 1999). 
 
5.9 Concluding remarks showing GIPRdn transgenic pigs in the 
 context of incretin hormone based mouse models 
In summary, impaired intravenous glucose tolerance, reduced insulin secretion 
capacity in a GST as well as reduced insulin secretion following Exendin-4 
stimulation in older GIPRdn transgenic pigs originally led to the suspicion of the 
presence of alterations in islet structure and/or islet integrity induced by the 
expression of a GIPRdn in the pancreatic islets. Quantitative islet isolation together 
with quantitative stereological analyses proved this suspicion by revealing a marked 
reduction of pancreatic islet and β-cell mass in GIPRdn transgenic pigs. These results 
are in line with previous evidence for a trophic action of GIP on β-cells in vitro. 
Proliferative as well as anti-apoptotic actions of GIP have been evaluated by the use 
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of heterologous cells transfected with the GIPR, β-cell lines, or murine islets and 
include activation of cAMP/PKA, PKA/CREB, MAPK and PI3K/Akt-PKB signaling 
modules, reductions in caspase-3 activity, and down-regulation of Bax gene 
transcription (Kim et al. 2005b; Ehses et al. 2003; Trumper et al. 2002; Trumper et al. 
2001). Also, GIP was found to reduce biochemical markers associated with 
endoplasmatic reticulum (ER) stress in islet cell lines after induction of ER stress in 
vitro (Yusta et al. 2006). In vivo, infusion of GIP via a micro-osmotic pump into 
Vancouver diabetic fatty Zucker rats for two weeks led to down-regulation of the pro-
apoptotic Bax gene and up-regulation of the anti-apoptotic Bcl-2 gene (Kim et al. 
2005b). GIPR knockout mice provided no evidence that GIPR action is required for 
the maintenance of islet and β-cell integrity in vivo (Hansotia & Drucker 2005; Pamir 
et al. 2003; Brubaker & Drucker 2004). Findings on islet morphology of GIPR-/- mice 
are quite controversial. GIPR-/- mice were shown to exhibit a paradoxical increase in 
relative β-cell area (referring to pancreas area) of ~45% (Pamir et al. 2003), whereas 
the total insulin content of pancreata and insulin mRNA levels in the fed state were 
significantly reduced compared to controls (Pamir et al. 2003). Elsewhere, no 
histological abnormalities were found in the pancreas of GIPR-/- mice (Miyawaki et al. 
1999). Also, GIPR-/- mice showed no changes in islet-cell distribution (Pamir et al. 
2003) and normal glucose tolerance in an intraperitoneal glucose tolerance test 
considering glucose and insulin levels (Miyawaki et al. 1999; Hansotia et al. 2004). 
These findings led to the conclusion that in vivo, the function of GIP is primarily 
restricted to that of an incretin (Hansotia et al. 2004). 
It has been suggested that the relatively mild phenotype of GIPR-/- mice may result 
from compensatory mechanisms, e.g. the up-regulation of the GLP-1 system 
(Hansotia & Drucker 2005). Islets from GIPR-/- mice were shown to exhibit increased 
sensitivity to exogenous GLP-1 (Pamir et al. 2003). Compensatory mechanisms may 
also preserve the integrity of pancreatic islets in GIPR-/- mice. In GLP-1R-/- mice 
compensatory mechanisms are also present and might serve to enhance β-cell 
function in the absence of GLP-1 signaling. Mice lacking a functional GLP-1R exhibit 
increased GIP secretion following glucose challenge and increased GIP stimulated 
insulin release from the perfused pancreas or isolated islets (Flamez et al. 1999; 
Pederson et al. 1998). Thus, phenotypical characteristics of GIPR-/- and GLP-1R-/- 
mice might not reflect all essential functions of GIP and GLP-1. GLP-1R-/- mice 
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showed no aberrant total β-cell volume and numbers as well as similar insulin and 
glucagon content compared to controls. However, alterations in islet topography with 
α–cells being more centrally located than in controls (Ling et al. 2001) as well as 
abnormal glycemic excursion but no difference in insulin levels in an intraperitoneal 
glucose tolerance test were found (Hansotia et al. 2004; Scrocchi et al. 1996). 
The functional overlap of the GIP and GLP-1 systems was demonstrated by the fact 
that double mutant mice (DIRKO) lacking functional expression of both the GIPR and 
the GLP-1R exhibited more severe glucose intolerance than the individual mutants 
following oral glucose challenge (Hansotia et al. 2004; Preitner et al. 2004). 
However, also these double mutant animals did not develop diabetes mellitus 
indicated by normal fasting blood glucose levels. This was in accordance with 
findings that total pancreatic insulin content in the fasted state was normal and no 
apparent difference could be detected in the number and size of islets of DIRKO 
mice compared to controls. 
In contrast, two lines of GIPRdn transgenic mice were characterized by early-onset 
diabetes mellitus (three weeks of age) indicated by severe glucosuria and fasting 
hyperglycemia (Volz 1997) coming along with disturbed development of the 
endocrine pancreas. Results obtained from GIPRdn transgenic mice are indicative for 
an essential role of the GIP/GIPR axis in the development of the endocrine pancreas. 
GIPRdn transgenic mice display a large reduction in islet and beta cell mass, and 
clear reduction of islet neogenesis at 10 days of age, a time point when incretin 
hormones are not yet essential for glucose homeostasis, and thus transgenic mice 
did not display hyperglycemia (Herbach et al. 2005). 
However, the massive changes detected were unexpected especially in the context 
that a third line of GIPRdn transgenic mice showed reduced oral glucose tolerance, 
but neither a full-blown diabetes mellitus nor structural (islet cell distribution and 
composition) changes of the pancreatic islets. 
The difference between diabetic GIPRdn transgenic mouse lines and the pig lines 
may be related to differences in expression levels of the transgene, possibly 
originating from species-dependent promoter activity. Moreover, proximity of the 
transgene integration site as well as the integrated copy number of the transgene 
could also influence transgene expression level. A high level of overexpression of a 
dominant-negative receptor may cause - in part - nonspecific effects, e.g. by 
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squelching of G proteins. It is possible that signal transduction pathways are 
disturbed in general in GIPRdn transgenic mice, leading to a failure to increase 
intracellular cAMP levels. This may not only affect the GIP/GIPR axis but also the 
GLP-1/GLP-1R axis and maybe other components being involved in insulin 
secretion. Most likely due to the severe changes of the endocrine pancreas, neither 
stimulation with glucose nor glucose + GIP or glucose + GLP-1 was able to augment 
serum insulin levels in diabetic GIPRdn transgenic mice in a subcutaneous glucose 
tolerance test. However, GLP-1 but not GIP was capable to reduce the AUC for 
glucose, which is most likely related to inhibitory effects of GLP-1 on glucagon 
secretion from the α-cells as has been shown in these mice (Herbach et al. 2005). In 
vitro signal transduction studies using isolated islets from diabetic GIPRdn transgenic 
mice could not be performed so far since it was not possible to isolate intact islets 
from these mice. Thus, specific relation of the diabetic phenotype to the expression 
of the GIPRdn transgene or possible differences concerning signal transduction 
between the 2 diabetic mouse lines and the glucose intolerant mouse line could not 
be proven so far. There is evidence that diabetic GIPRdn mouse lines have more 
integrated copies of the transgene compared to the glucose intolerant mouse line 
which could have resulted in the phenotypic differences (Volz unpublished data). 
It can be expected that GIPRdn transgenic pigs exhibit some degree of insulin 
deficiency due to reduced islet/β-cell mass. In general, insulin deficiency has impact 
on various organs. The glucose uptake in adipose tissue is reduced. Thus, 
lipogenesis is low and lipolysis increased. Also, the uptake of glucose into skeletal 
muscle tissue is reduced. Further, disturbed amino acid uptake and thus protein 
synthesis as well as increased proteolysis leads to catabolism in muscular tissues. 
Also, glycogen synthase in the skeletal muscle being stimulated by insulin is less 
active. Increased glycogenolysis and gluconeogenesis are present in the liver 
(Berger 2000). 
However, GIPRdn transgenic pigs have not deteriorated to a full-blown diabetic 
phenotype so far, indicated by normal fasting blood glucose and serum fructosamine 
levels. There is no direct evidence for insulin resistance in GIPRdn transgenic pigs. 
Neither fasting hyperinsulinemia nor hyperinsulinema following an oral glucose load 
are present. Although absolute insulin deficiency due to reduced β-cell mass might 
mask insulin resistance, presence of insulin resistance seems not likely because 
 115
Discussion 
GIPRdn transgenic pigs have not developed a diabetic phenotype so far. The fact that 
transgenic pigs stay normoglycemic despite a distinct reduction of β-cell mass could 
even be related to an increased sensitivity of peripheral tissues to insulin (fat, skeletal 
muscle, liver). 
Relative β-cell volume (β-cell area/exocrine area) of weight-matched type 2 diabetic 
patients was found to be decreased by 40-60% compared to controls. Interestingly, 
also subjects in a prediabetic state showed a 40% decrease in relative β-cell volume 
(Butler et al. 2003; Yoon et al. 2003). Evaluation of glucose metabolism of 60% 
pancreatectomized rats following a short period of regeneration for the β-cells (loss of 
β-cell mass was estimated 40% following the regeneration phase) revealed 
normoglycmia indicating that normal β-cell mass is more than adequate (Leahy et al. 
1988). Thus, pigs might be able to tolerate a distinct loss of β-cell mass without 
developing a diabetic phenotype. 
In summary, GIPRdn transgenic pigs proved an essential role of the GIP/GIPR axis 
for the maintenance of long-term pancreatic islet integrity. Possible compensatory 
mechanisms might not be triggered because the endogenous GIPR is still present in 
GIPRdn transgenic pigs as compared to single incretin receptor knockout mice. Even 
in DIRKO mice possible compensatory mechanisms of functionally related peptides 
to enhance β-cell function cannot be excluded (Hansotia et al. 2004). For example, 
PACAP receptors are known to be expressed on β-cells. Mice lacking a functional 
PAC 1 receptor revealed a reduced glucose-stimulated insulin secretion in vivo and 
in vitro (Jamen et al. 2000). Additionally, long-term glucose toxicity is absent in 
GIPRdn transgenic pigs because they exhibit normal fasting glucose levels until at 
least 15 months of age. Importantly, a direct coherence that GIPR action is required 
for the maintenance of islet and β-cell mass has not been determined so far in a 
large animal model. The pig was chosen to generate this animal model because 
many physiological characteristics of the pig are more similar to the human than 
those of the mouse especially considering the gastrointestinal tract. Furthermore, the 
large size of a pig model facilitates a plethora of physiological and molecular studies 
as well as therapeutic trials that cannot be performed in the small rodent models. 
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6 Perspectives 
 
GIPRdn transgenic pigs seem to be a very valuable animal model for numerous 
further investigations. First, islet and β-cell mass should be determined in different 
age groups to narrow down the onset of the alterations within the endocrine 
pancreas. Additionally, a detailed characterization of the mechanisms by which GIP 
supports islet maintenance as well as the search for targets to bypass or overcome 
the GIPR signaling defect would be of great interest. This could be accomplished by 
quantitative evaluation of mitotic (for example by determination of the rate of DNA 
synthesis by enzyme-linked detection of 5-bromo-deoxyuridine (BrdU) incorporation 
or detection of Ki67-antigen via immunohistochemistry) and apoptotic indices (for 
example immunohistochemical detection of caspases, especially caspase-3, or 
TUNEL assay). Qualitative assessment of several test slides immunohistochemically 
stained for caspase-3 from pancreatic tissue of one GIPRdn transgenic and one 
control pig did not show a visible striking difference between the two animals, 
although a greater number of samples and animals has to be evaluated quantitatively 
to obtain a definitive result. Second, it might be helpful to explore signaling pathway 
modules known to be involved in proliferative and anti-apoptotic actions of GIP on the 
RNA and protein level. In this context, holistic transcriptome and proteome analyses 
might be useful. As the expression of a dominant-negative GIPR mimics the situation 
in human type 2 diabetic patients whose insulinotropic action of GIP was found to be 
greatly reduced up to almost absent, findings from GIPRdn transgenic pigs may give 
new insights into the pathogenetic consequences of impaired GIP action. Yet another 
interesting question this animal model could be used for would be the development of 
in vivo imaging techniques to assess the total islet cell mass of type 2 diabetic 
patients (Gotthardt et al. 2006). This would be very useful for evaluation of the 
etiopathology and response to therapeutics in type 2 diabetic patients as increased 
apoptosis coming along with reduced proliferation of β-cells plays an important 
pathogenetic role in type 2 diabetes mellitus. Additionally, GIPRdn transgenic pigs 
might be very valuable for the development and preclinical evaluation of incretin 
modulatory therapies. Especially interesting is the question whether incretin hormone 
based therapeutics (incretin mimetics like Exendin-4; GLP-1 analogues; DPP-4-
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inhibitors) are able to stimulate β-cell proliferation and –neogenesis and inhibit β-cell 
apoptosis in human type 2 diabetic patients as has been shown in rodents (Gallwitz 
2006a; Mu et al. 2006). Proof of this suspicion in therapeutic trials using GIPRdn 
transgenic pigs would be especially valuable and therapeutic dosages could be 
evaluated in an animal species closely related to the human. Last, it will be 
interesting to see whether GIPRdn transgenic pigs develop diabetes with increasing 
age. 
 118
Summary 
7 Summary 
 
Transgenic pigs expressing a dominant-negative glucose-dependent 
insulinotropic polypeptide receptor – a novel animal model for studying the 
consequences of impaired incretin hormone function 
 
The incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and 
glucagon-like peptide-1 (GLP-1) are secreted by enteroendocrine cells in response to 
nutrients like fat and glucose and mediate the incretin effect. The incretin effect 
describes the phenomenon that an oral glucose load elicits a higher insulin response 
than an intravenous glucose infusion. In patients with type 2 diabetes mellitus, the 
overall incretin effect is reduced. This fact is mostly put down to an obviously lowered 
insulinotropic effect of GIP, while the effect of GLP-1 is vastly preserved. In order to 
better understand the consequences of an impaired function of GIP, knockout mice 
lacking a functional GIP receptor (GIPR-/-) as well as transgenic mice expressing a 
dominant-negative GIPR (GIPRdn) were established. While GIPR-/- mice show only 
relatively mild changes in glucose homeostasis, GIPRdn mice display a distinct 
diabetic phenotype due to disturbed development of the endocrine pancreas. To 
further clarify the underlying mechanisms we used an efficient gene transfer 
technology based on lentiviral vectors to generate transgenic pigs expressing a 
GIPRdn under the control of the rat insulin 2 gene promoter (RIP2). Expression of the 
GIPRdn transgene could be determined in isolated porcine islets of Langerhans by 
RT-PCR. As expected, the insulin release in response to intravenous administration 
of porcine GIP, which was evaluated in two age groups, turned out to be smaller in 
transgenic pigs compared to controls although the difference did not reach statistical 
significance in the younger animals. GIPRdn transgenic pigs develop normally and do 
not display diabetes mellitus up to at least 15 month of age. Weekly measured 
fasting blood glucose levels in transgenic animals did not show a significant 
difference compared to control pigs. The same was true for monthly determined 
fructosamine levels. However, GIPRdn transgenic pigs at 5 month of age exhibited a 
reduced initial insulin release and higher glucose levels in an oral glucose tolerance 
test than non-transgenic littermate controls. Intravenous glucose tolerance as well as 
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insulin secretion following intravenous injection of Exendin-4, a GLP-1 receptor 
agonist was preserved in younger GIPRdn transgenic pigs, but impaired in older ones 
compared to non-transgenic controls. Impaired intravenous glucose tolerance, 
reduced glucagon-induced insulin secretion capacity and impaired insulin secretion 
following stimulation with Exendin-4 in older GIPRdn transgenic pigs led to the 
assumption that expression of a GIPRdn in the pancreatic islets might cause 
alterations in islet composition and/or islet integrity. Quantitative islet isolation as well 
as quantitative stereological analyses of the pancreas proved this assumption. 
Significantly diminished islet recovery in transgenic pigs compared to their non-
transgenic littermate controls was determined by quantitative islet isolation. 
Quantitative stereological analyses of the pancreas revealed a marked reduction in 
islet and β-cell mass of GIPRdn transgenic pigs, but no difference in isolated β-cells 
within the exocrine pancreas which is an indicator for islet neogenesis compared to 
controls. 
These findings demonstrate for the first time that impaired GIPR function is sufficient 
to cause the loss of β-cell mass in a large animal model. Importantly, many 
physiological characteristics of the pig are more similar to the human than those of 
the mouse. Moreover, the large size of a pig model facilitates a plethora of 
physiological and molecular studies as well as therapeutic trials that cannot be 
performed in the small rodent models. Thus, the GIPRdn transgenic pig is a novel, 
clinically relevant animal model for type 2 diabetes mellitus research. 
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8 Zusammenfassung 
 
Expression eines dominant-negativen Rezeptors 
für das Glukose-abhängige insulinotrope Polypeptid in transgenen Schweinen 
– ein neues Tiermodell zur Untersuchung der Auswirkungen einer 
verminderten Inkretinhormonfunktion 
 
Die Inkretinhormone glucose-dependent insulinotropic polypeptide (GIP) und 
glucagon-like peptide-1 werden infolge von Nahrungsreizen wie Glukose oder Fett 
von enteroendokrinen Zellen aus dem Darm ausgeschüttet und vermitteln den 
Inkretineffekt. Der Inkretineffekt beschreibt das Phänomen, dass eine orale 
Glukosegabe im Vergleich zu einer intravenösen Glukoseinfusion einen stärkeren 
Konzentrationsanstieg von Insulin im Blut auslöst. Bei Patienten mit Typ 2 Diabetes 
mellitus konnte eine deutlich reduzierte insulinotrope Wirkung von GIP detektiert 
werden, während die Wirkung von GLP-1 weitgehend erhalten bleibt. Um die Folgen 
einer gestörten Funktion von GIP besser zu verstehen, wurden GIP Rezeptor 
knockout Mäuse (GIPR-/-) sowie transgene Mäuse, die einen dominant-negativen 
GIPR (GIPRdn) exprimieren, erstellt. Während GIPR-/- Mäuse nur relativ geringe 
Veränderungen im Glukosemetabolismus zeigen, entwickeln GIPRdn transgene 
Mäuse einen ausgeprägten diabetischen Phänotyp infolge einer gestörten 
postnatalen Ausbildung des endokrinen Pankreas. Um ein Großtiermodell mit 
gestörter GIP-Funktion zu generieren, wurde eine hocheffiziente, auf lentiviralen 
Vektoren basierende Gentransfertechnologie verwendet. Transgene Schweine, die 
den GIPRdn unter der Kontrolle des Ratten Insulin 2 Promotors (RIP2) exprimieren, 
entwickeln sich normal. Mittels RT-PCR Analysen von RNA aus isolierten 
Langerhansschen Inseln konnte gezeigt werden, dass die mRNA für den mutierten 
GIPR im endokrinen Pankreas exprimiert wird. Erwartungsgemäß konnte bei GIPRdn 
transgenen Tieren zweier Altersgruppen im Vergleich zu nicht transgenen, gleich 
alten Kontrolltieren eine verminderte Insulinsekretion nach intravenöser Applikation 
von porcinem GIP festgestellt werden, wenn auch der Unterschied bei den jüngeren 
Tieren keine statistische Signifikanz erreichte. Anhand der Nüchternblutglukose- und 
Fruktosaminkonzentration konnte gezeigt werden, dass transgene Schweine bis zu 
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einem Alter von mindestens 15 Monaten keinen diabetischen Phänotyp entwickeln. 
Im oralen Glukosetoleranztest hingegen zeigten GIPRdn transgene Schweine im Alter 
von fünf Monaten eine verminderte initiale Insulinfreisetzung sowie erhöhte 
Blutglukosespiegel. Die intravenöse Glukosetoleranz sowie die Insulinsekretion nach 
intravenöser Applikation von Exendin-4, einem GLP-1R Agonisten, war normal bei 
jüngeren transgenen Tieren und vermindert bei älteren GIPRdn transgenen 
Schweinen im Vergleich zu gleich alten Kontrolltieren. 
Aufgrund verminderter intravenöser Glukosetoleranz, reduzierter Glukagon-
induzierter Insulinsekretionskapazität, sowie einer verminderten Insulinsekretion 
nach Stimulation mit Exendin-4 bei älteren GIPRdn transgenen Schweinen im 
Vergleich zu gleich alten Kontrolltieren, wurde eine mögliche Auswirkung der 
Expression eines GIPRdn in den Langerhansschen Inseln auf die Morphologie 
und/oder die Integrität der Langerhansschen Inseln vermutet. Eine quantitative 
Inselisolation sowie quantitativ-stereologische Untersuchungen des Pankreas 
konnten diesen Verdacht bestätigen. Aus Pancreata von GIPRdn transgenen 
Schweinen konnten signifikant weniger Langerhanssche Inseln isoliert werden. Die 
quantitativ-stereologischen Untersuchungen zeigten signifikant geringere 
Gesamtinselvolumina sowie Gesamtbetazellvolumina bei transgenen Schweinen im 
Vergleich zu Kontrolltieren. Kein Unterschied ergab sich im Gesamtvolumen der 
isolierten β-Zellen im Pankreas, einem Indikator für Inselneogenese. 
Diese Ergebnisse zeigen zum ersten Mal in einem Großtiermodell, dass die 
Expression eines GIPRdn in den Langerhansschen Inseln ausreicht, um eine 
Verminderung der β-Zellmasse zu verursachen. Das Schwein als Modelltier ist von 
großem Vorteil, da physiologische Charakteristika vieler Organsysteme des 
Schweines dem Menschen ähnlicher sind als die der Maus. Das Modelltier Schwein 
erleichtert bzw. ermöglicht zudem zahlreiche physiologische, molekularbiologische 
sowie klinische Untersuchungen inklusive Therapiestudien. Somit kann das GIPRdn 
transgene Schwein als ein klinisch relevantes Tiermodell für die Typ 2 
Diabetesforschung gesehen werden. 
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